<!DOCTYPE html>
<html lang="en">
    <head>
        <title>displaCy</title>
    </head>

    <body style="font-size: 16px; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Helvetica, Arial, sans-serif, 'Apple Color Emoji', 'Segoe UI Emoji', 'Segoe UI Symbol'; padding: 4rem 2rem; direction: ltr">
<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D90110496">90110496</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Anti-Ro ( SSA ) autoantibodies are associated with 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 beta genes in systemic lupus erythematosus patients. Several of the heterogeneous clinical manifestations of systemic lupus erythematosus have been associated with specific autoantibodies. Associations between HLA class II antigens and autoantibodies to the ribonucleoproteins Ro ( SSA ) and La ( SSB ) have been reported in these patients. Because HLA class II molecules present antigen to T cell receptors ( TCRs ) , we have searched for a 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 gene associated with the production of anti-Ro ( SSA ) antibodies. A pair of restriction fragment length polymorphisms ( RFLPs ) , one of which hybridizes to the 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 constant region C beta 1 and the other to the C beta 2 gene, has been identified, suggesting these may be genotypic markers for an extended region of the 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 beta locus. This RFLP pair occurs in 76% of patients with Ro ( SSA ) precipitins, 84% of anti-Ro ( SSA ) -positive patients lacking La ( SSB ) precipitins, but only 41% of the patients lacking both precipitins ( P = 0.0004 ) . This disproportionate occurrence in a subset of lupus patients indicates that these RFLPs are not disease susceptibility markers, but rather are important markers for 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 genes whose products are involved in the production of anti-Ro ( SSA ) antibodies. The majority of patients who have these RFLPs and HLA class II antigens previously associated with the anti-Ro ( SSA ) response make this antibody, suggesting that interactions between products of these loci occur in response to Ro ( SSA ) . </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D90124644">90124644</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Reactivity of lymphocytes to a progesterone receptor-specific monoclonal antibody. In this study we present evidence for reactivity of pregnancy lymphocytes, but not nonpregnancy lymphocytes, with the progesterone receptor-specific monoclonal antibody mPRI. Using an avidin-biotin peroxidase detection system, we found a nuclear staining in 14.6 +/- 3.7% ( mean +/- SEM, N = 27 ) of pregnancy lymphocytes, while only 0.47 +/- 0.33% ( mean +/- SEM, N = 15 ) of nonpregnancy lymphocytes reacted with the antibody. To characterize the receptor-bearing subset, CD8+ and CD4+ cells were depleted by complement-dependent lysis. Depletion of CD8+ cells was accompanied by 62 +/- 18% loss of progesterone receptor-bearing cells, while depletion of CD4+ cells resulted in a twofold increase in the number of positively staining lymphocytes. In nonpregnancy lymphocytes a 3-day PHA treatment, as well as allogeneic stimulation, resulted in a significant increase in the number of receptor-containing cells. These results suggest that pregnancy, but not nonpregnancy, lymphocytes contain progesterone binding structures, and that these are inducible by mitogenic or alloantigenic stimuli. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D90140708">90140708</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Two distinct 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 that bind the immunoglobulin enhancer microE5 / kappa 2 motif. Activity of the immunoglobulin heavy and kappa light chain gene enhancers depends on a complex interplay of ubiquitous and developmentally regulated proteins. Two 
<mark class="entity" style="background: #DDBDFE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complementary DNAs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">164</span>
</mark>
 were isolated that encode proteins, denoted ITF-1 and ITF-2, that are expressed in a variety of cell types and bind the microE5 / kappa 2 motif found in both heavy and kappa light chain enhancers. The 
<mark class="entity" style="background: #DDBDFE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complementary DNAs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">164</span>
</mark>
 are the products of distinct genes, yet both ITF-1 and ITF-2 are structurally and functionally similar. The two proteins interact with one another through their putative helix-loop-helix motifs and each possesses a distinct domain that dictates 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D90376424">90376424</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Cell-specific differences in 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 of 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human immunodeficiency virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 and beta interferon promoters by 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
. Three aspects of the involvement of 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 in 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human immunodeficiency virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 ( 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 ) pathogenesis were examined. 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tumor necrosis factor alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ( 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ) mRNA production was analyzed by 
<mark class="entity" style="background: #BFCBCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polymerase chain reaction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">156</span>
</mark>
 amplification in monocytic 
<mark class="entity" style="background: #CE9CBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    U937 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">147</span>
</mark>
 and in a chronically 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 infected U937 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 ( U9-IIIB ) . 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 RNA was undetectable in 
<mark class="entity" style="background: #CE9CBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    U937 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">147</span>
</mark>
, whereas a low constitutive level was detected in U9-IIIB cells. Paramyxovirus infection induced a 5- to 10-fold increase in the steady-state level of 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 RNA in U9-IIIB cells compared with 
<mark class="entity" style="background: #CE9CBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    U937 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">147</span>
</mark>
, suggesting that 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
-infected 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
 produced higher levels of 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 than did normal cells after a secondary virus infection. The effects of 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 on 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 were examined by 
<mark class="entity" style="background: #EA9DCC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transient expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">224</span>
</mark>
 assays using reporter chloramphenicol acetyltransferase plasmids linked to 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 from the 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 long terminal repeat ( LTR ) and the beta interferon promoter. In U937 and Jurkat T lymphoid cells, the inducibility of the different hybrid promoters by 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 or 
<mark class="entity" style="background: #BDBDEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phorbol ester
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">215</span>
</mark>
 varied in a cell type- and promoter context-specific manner; the levels of gene 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activity of NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
-containing plasmids correlated directly with induction of 
<mark class="entity" style="background: #ACF9FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">69</span>
</mark>
 activity. Although the intact beta interferon promoter was only weakly stimulated by 
<mark class="entity" style="background: #BDBDEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phorbol ester
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">215</span>
</mark>
 or 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
, multimers of the PRDII 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
-binding domain were inducible by both agents. 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 was able to increase expression of the 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 LTR in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
, but in 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
, 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 did not induce the 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 LTR above a constitutive level of activity. This level of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
-independent activity appears to be sufficient for virus multiplication, since 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 treatment had no effect on the kinetics of de novo 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 type 1 ( HIV-1 ) infection and viral RNA production in 
<mark class="entity" style="background: #CE9CBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    U937 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">147</span>
</mark>
. However, in 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
, 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 dramatically enhanced the spread of HIV-1 through the cell population and increased viral RNA synthesis, indicating that in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 HIV-1 multiplication was stimulated by 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 treatment. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D91164434">91164434</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 on mononuclear leukocytes in 
<mark class="entity" style="background: #CFBCEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">58</span>
</mark>
. Several lines of evidence suggest disturbances of the hypothalamic-pituitary-adrenal ( HPA ) system in 
<mark class="entity" style="background: #CFBCEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Alzheimer's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">58</span>
</mark>
 ( 
<mark class="entity" style="background: #CFBCEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">58</span>
</mark>
 ) . In an exploration of the potential role of the 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ( 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ) in 
<mark class="entity" style="background: #CFBCEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">58</span>
</mark>
, 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 density and affinity were assessed on mononuclear leukocytes of 12 
<mark class="entity" style="background: #CFBCEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">58</span>
</mark>
 patients and 12 healthy controls. 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 binding characteristics did not differ between patients and controls or between patients subdivided according to diagnosis or associated clinical features. These data suggest that the abnormalities of the HPA system in 
<mark class="entity" style="background: #CFBCEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AD
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">58</span>
</mark>
 are not related to a 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 deficiency. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D91190842">91190842</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Purification of 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
, a 
<mark class="entity" style="background: #9CAEC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell-specific transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">121</span>
</mark>
 that activates the 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 C alpha gene enhancer in a context-
<mark class="entity" style="background: #CAE9FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent manner
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">190</span>
</mark>
. The differentiation of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 into functionally diverse subpopulations is controlled in part, by 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 and silencing; however, little is known in detail about the proteins that influence this developmental process. We have purified a new T-cell-specific factor, 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
, that is implicated in the activation of genes encoding a major component of the human 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 ( 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 ) . 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
, originally identified and purified through its binding sites on the HIV-1 promoter, was found to bind to the 
<mark class="entity" style="background: #E9FEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR alpha enhancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">44</span>
</mark>
 and to promoters for several genes expressed at significantly earlier stages of T-cell development than the 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 alpha gene ( e.g., p56 lck and CD3 delta ) . Sequences related to the 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 binding motif ( 5'--3' ) are also found in the human 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 delta ( and possibly 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 beta ) enhancers. Southwestern and gel renaturation experiments with the use of purified protein fractions revealed that 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 activity is derived from a family of 57- to 53-kD proteins that are abundantly expressed in mature and immature 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
 ( Jurkat, CCRF-CEM ) and not in mature 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 ( JY, Namalwa ) or nonlymphoid ( HeLa ) 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
. A small 95-bp fragment of the 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 alpha control region that contains the 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 binding site juxtaposed between a cAMP-response element ( the CRE or T alpha 1 motif ) and the binding site for a distinct lymphoid-specific protein ( TCF-2 alpha ) behaved as a potent T-cell-specific enhancer in vivo. Tandem copies of this enhancer functioned synergistically in mature ( Jurkat ) 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
 as well as resting and activated immature ( CCRF-CEM ) 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
. Mutation of the 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 binding site diminished enhancer activity and disrupted the synergism observed in vivo between tandem enhancer repeats. The 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 binding site was also required for 
<mark class="entity" style="background: #E9FEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR alpha enhancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">44</span>
</mark>
 activity in transcriptionally active extracts from Jurkat but not HeLa cells, confirming that 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 is a 
<mark class="entity" style="background: #9CAEC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell-specific transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">121</span>
</mark>
. Curiously, the 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 binding element was inactive in vivo when removed from its neighboring elements on the 
<mark class="entity" style="background: #E9FEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR alpha enhancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">44</span>
</mark>
 and positioned in one or more copies upstream of a heterologous promoter. Thus, the 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 of 
<mark class="entity" style="background: #DBEBFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCF-1 alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">56</span>
</mark>
 appears to depend on the TCF-2 alpha and T alpha 1 ( CREB ) 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 and the context of its binding site within the 
<mark class="entity" style="background: #E9FEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR alpha enhancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">44</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D91321794">91321794</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #DAEBAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Inhibition of HIV-1 replication
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">260</span>
</mark>
 and 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 by cysteine and cysteine derivatives. HIV-1 proviral DNA contains two binding sites for the 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 NF-kappa B. HIV-1-infected individuals have, on average, abnormally high levels of 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumour necrosis factor alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ( 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ) and abnormally low plasma cysteine levels. We therefore investigated the effects of cysteine and related thiols on HIV-1 replication and 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 expression. The experiments in this report show that cysteine or N-acetylcysteine ( NAC ) raise the intracellular glutathione ( GSH ) level and 
<mark class="entity" style="background: #DAEBAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inhibit HIV-1 replication
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">260</span>
</mark>
 in persistently infected Molt-4 and 
<mark class="entity" style="background: #CE9CBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    U937 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">147</span>
</mark>
. However, 
<mark class="entity" style="background: #DAEBAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inhibition of HIV-1 replication
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">260</span>
</mark>
 appears not to be directly correlated with GSH levels. Cysteine and NAC also inhibit 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 as determined by 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assays
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 and chloramphenicol acetyl-transferase ( CAT ) 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 under control of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 binding sites in uninfected cells. This suggests that the cysteine deficiency in HIV-1-infected individuals may cause an over-expression of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
-dependent genes and enhance HIV-1 replication. NAC may be considered for the treatment of HIV-1-infected individuals. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D91363265">91363265</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Regulation of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in human mononuclear cells: effects of glucocorticoid treatment, 
<mark class="entity" style="background: #EEB9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cushing's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">179</span>
</mark>
 and ketoconazole. 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ( 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ) were determined by a whole cell assay in human mononulear leukocytes ( hMNL ) from control subjects, patients receiving glucocorticoid therapy for systemic diseases and 
<mark class="entity" style="background: #EEB9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cushing's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">179</span>
</mark>
 patients with or without ketoconazole therapy. Prolonged corticosteroid treatment resulted in down-regulation of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
, while the mean level of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in 
<mark class="entity" style="background: #EEB9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cushing's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">179</span>
</mark>
 was normal. In this group, however, receptor levels and morning plasma cortisol values showed a negative correlation, indicating a subtle down-regulatory effect. Furthermore, 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 were unaltered after these patients received ketoconazole, in spite of a marked reduction in morning plasma cortisol and urinary free cortisol. We also observed that ketoconazole was a weak competitor of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in intact cells, although it significantly inhibited [3H] dexamethasone binding in cytosolic preparations from rat tissues. The results suggested that 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in hMNL are down-regulated by synthetic steroids given in vivo, but they showed very mild down-regulation in hypercortisolemic patients suffering from 
<mark class="entity" style="background: #EEB9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cushing's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">179</span>
</mark>
. Finally, we did not observed either up-regulation or antagonism of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 by ketoconazole treatment, at the time that cortisol levels of patients with 
<mark class="entity" style="background: #EEB9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cushing's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">179</span>
</mark>
 were reduced. This indicates that the beneficial effects of ketoconazole in 
<mark class="entity" style="background: #EEB9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cushing's disease
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">179</span>
</mark>
 are due to adrenal cortisol suppression and not to interaction with 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 of target cells, and that the process of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 regulation in hMNL is a complex phenomenon awaiting further elucidation. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D92052106">92052106</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Negative regulation of 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human immunodeficiency virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 type 1 expression in monocytes: role of the 65-kDa plus 50-kDa 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 dimer. Although 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
 can provide a reservoir for viral production in vivo, their regulation of 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human immunodeficiency virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 type 1 ( HIV-1 ) transcription can be either latent, restricted, or productive. These differences in 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 have not been molecularly defined. In 
<mark class="entity" style="background: #CEFDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    THP-1 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">145</span>
</mark>
 with restricted 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 expression, there is an absence of DNA-protein binding complex formation with the HIV-1 promoter-enhancer associated with markedly less viral RNA production. This absence of binding was localized to the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 region of the HIV-1 enhancer; the 65-kDa plus 50-kDa 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 heterodimer was preferentially lost. Adding purified 
<mark class="entity" style="background: #BCFEDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B protein
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">76</span>
</mark>
 to 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 from cells with restricted expression overcomes this lack of binding. In addition, treatment of these 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 with sodium deoxycholate restored their ability to form the heterodimer, suggesting the presence of an inhibitor of 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
. Furthermore, treatment of 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 from these cells that had restricted expression with lipopolysaccharide increased viral production and 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
. Antiserum specific for 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 binding proteins, but not c-rel-specific antiserum, disrupted heterodimer complex formation. Thus, both 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
-binding complexes are needed for optimal viral transcription. Binding of the 65-kDa plus 50-kDa heterodimer to the HIV-1 enhancer can be negatively regulated in monocytes, providing one mechanism restricting HIV-1 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D92134262">92134262</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">A novel primer extension method to detect the number of 
<mark class="entity" style="background: #EECEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAG repeats
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">102</span>
</mark>
 in the androgen receptor gene in families with X-linked spinal and bulbar muscular atrophy. X-linked spinal and bulbar muscular atrophy ( SBMA ) , an adult-onset form of motor neuron disease, was recently reported to be caused by amplification of the 
<mark class="entity" style="background: #EECEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAG repeats
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">102</span>
</mark>
 in the androgen receptor gene. We report here a simple and rapid strategy to detect the precise number of the CAGs. After the DNA fragment containing the 
<mark class="entity" style="background: #EECEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAG repeats
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">102</span>
</mark>
 is amplified by the 
<mark class="entity" style="background: #BFCBCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polymerase chain reaction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">156</span>
</mark>
, a primer extension is carried out; the extension of the end-labelled reverse primer adjacent to 3' end of 
<mark class="entity" style="background: #EECEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAG repeats
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">102</span>
</mark>
 stops at the first T after 
<mark class="entity" style="background: #EECEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAG repeats
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">102</span>
</mark>
 with the incorporation of dideoxy ATP in the reaction mixture. The resultant primer products are analysed by denaturing polyacrylamide gel electrophoresis and autoradiography. This method could be quite useful to detect not only 
<mark class="entity" style="background: #EECEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CAG repeats
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">102</span>
</mark>
 in SBMA but also other polymorphic dinucleotide and trinucleotide repeats. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D92135145">92135145</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Activity of the 
<mark class="entity" style="background: #FCFBEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B enhancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">71</span>
</mark>
 of the interleukin-2 
<mark class="entity" style="background: #BFB9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    receptor alpha chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">45</span>
</mark>
 in somatic cell hybrids is accompanied by the nuclear localization of NF-kappa B. The two 
<mark class="entity" style="background: #BCFEDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear proteins NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">76</span>
</mark>
 ( consisting of subunits p50 an dp65 ) and the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 subunit of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( p50 ) by itself, also called KBF1, are constitutively expressed and localized in the nucleus of the human 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
 IARC 301.5. In order to define the roles of these two factors, which bind to the same 
<mark class="entity" style="background: #FCFBEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B enhancers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">71</span>
</mark>
, in 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 we have prepared somatic cell hybrids between IARC 301.5 and a murine myeloma. Most hybrids express both KBF1 and 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 in their nuclei, but one hybrid expresses only KBF1. The 
<mark class="entity" style="background: #FCFBEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B enhancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">71</span>
</mark>
 of the gene encoding the interleukin-2 ( IL-2 ) 
<mark class="entity" style="background: #BFB9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    receptor alpha chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">45</span>
</mark>
 ( IL-2R alpha ) is functional only in the hybrids expressing nuclear NF-kappa B. These findings show that 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 is necessary to activate the 
<mark class="entity" style="background: #FCFBEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B enhancer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">71</span>
</mark>
, while KBF1 by itself is not sufficient. We propose that KBF1 is a competitive inhibitor of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 and discuss how these factors may be involved in the 
<mark class="entity" style="background: #EA9DCC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transient expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">224</span>
</mark>
 of IL-2 and IL-2 alpha genes during the immune response. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D92215726">92215726</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Kinetics of 
<mark class="entity" style="background: #9EEF9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear translocation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">304</span>
</mark>
 and turnover of the vitamin D receptor in human HL60 leukemia cells and 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
-coincident rise of DNA-relaxing activity in 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
. High affinity receptors ( VDR ) for 1,25-dihydroxycholecalciferol ( calcitriol ) are expressed in HL60 human leukemia cells and in low numbers in 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
 ( 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
 ) . 
<mark class="entity" style="background: #A9DE9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HL60 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">125</span>
</mark>
, expressing some characteristics of promyelocytes, can be induced to monocytoid differentiation by calcitriol. Specific 
<mark class="entity" style="background: #9EEF9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear translocation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">304</span>
</mark>
 of [3H]calcitriol / VDR was examined after exposure of whole cells to 10 ( -9 ) M / l calcitriol in the presence and absence of a 500-fold excess of unlabeled ligand and subsequent isolation of nuclei. Specific 
<mark class="entity" style="background: #9EEF9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear translocation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">304</span>
</mark>
 of [3H]calcitriol / VDR was found to be time dependent reaching a maximum of approximately 2100 binding sites / nucleus after 3 h of incubation in 
<mark class="entity" style="background: #A9DE9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HL60 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">125</span>
</mark>
, whereas a maximum of approximately 310 binding sites / nucleus was found after 3 h in 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
. Pulse exposure of HL60 to radiolabeled hormone for 3 h followed by culture in medium without serum and calcitriol lead to nuclear retention of approximately 1600 radiolabeled VDR by 8 h and approximately 1000 VDR by 24 h. Radiolabeled VDR disappeared from the 
<mark class="entity" style="background: #C9AABC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear compartment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">163</span>
</mark>
 with a halflife of approximately 30 min if cells were cultured with identical concentrations of unlabeled hormone after the pulse ( pulse / chase-experiments ) . No difference of VDR retention in pulse and pulse / chase-experiments was seen in 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
, where VDR halflife was approximately 30 min. No specific translocation into the 
<mark class="entity" style="background: #C9AABC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear compartment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">163</span>
</mark>
 was seen when isolated nuclei were incubated in [3H]calcitriol. Radiolabeled hormone / receptor complexes of nuclei isolated from cells exposed for 3 h to radiolabeled hormone-in contrast to identical experiments with intact cells-did not disappear from the 
<mark class="entity" style="background: #C9AABC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear compartment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">163</span>
</mark>
 upon incubation of nuclei with identical concentrations of the unlabeled compound. The activity of DNA relaxing enzymes ( e.g. topoisomerases I and II ) in 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 was measured using a PBR 322-relaxation-assay. Enhanced overall enzyme activity was found in 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 by 1 h after incubation with calcitriol ( final ethanol concentration 0.0001% v / v ) in HL60 and 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
. The enhanced activity disappeared after 2 h in 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
, whereas it was still enhanced by 4 h in HL60. No effect was seen in ethanol treated controls. We conclude that a specific 
<mark class="entity" style="background: #9EEF9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear translocation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">304</span>
</mark>
 mechanism exists for calcitriol in both cell types examined, most likely due to translocation of receptor proteins after hormone binding. Translocated hormone / receptor complexes compete for a limited number of specific nuclear binding sites. Enhanced activity of topoisomerases in 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 upon translocation of VDR might reflect interaction of both within the 
<mark class="entity" style="background: #C9AABC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear compartment
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">163</span>
</mark>
, thus initiating DNA-unwinding, a prerequisite of transcription initiation. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D92362919">92362919</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">[Age-related changes in glucocorticoid and mineralocorticoid receptors in lymphocytes of healthy persons and patients with hypertension] It has been found that the number of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in lymphocytes of the 
<mark class="entity" style="background: #BBEFAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">97</span>
</mark>
 of healthy elderly subjects increases, while the number of mineralocorticoid receptors decreases. The mechanisms of hormone-receptor interactions in hypertension are activated: the number of glucocorticoid and mineralocorticoid binding sites grows in hypertensive patients. Still a more essential rise in the number of receptors is observed in mid-age hypertensive patients than in elderly ones. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D93024468">93024468</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Characterization of a new tissue-specific 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 binding to the simian virus 40 enhancer TC-II ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) element. We have biochemically and functionally characterized a new 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
, NP-TCII, which is present in nuclei from unstimulated T and B lymphocytes but is not found in nonhematopoietic cells. This factor has a 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 specificity similar to that of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 but is unrelated to this or other 
<mark class="entity" style="background: #9DCCAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rel proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">309</span>
</mark>
 by functional and biochemical criteria. It can also be distinguished from other previously described lymphocyte-specific 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 proteins. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D93183827">93183827</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Expression of PILOT, a putative 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
, requires two signals and is cyclosporin A sensitive in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Few known genes ( IL-2, members of the IL-8 family, 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    interferon-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 ) are induced in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 only through the combined effect of phorbol myristic acetate ( PMA ) and a Ca ( 2+ ) -ionophore, and expression of only these genes can be fully suppressed by Cyclosporin A ( CyA ) . We have identified a putative 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
, designated PILOT, with an identical dual signal requirement for expression. Induction of the PILOT gene is detectable in human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 20 min following activation in the presence of cycloheximide and is fully suppressed by CyA. The PILOT protein has a calculated M ( r ) of 42.6 kDa and contains three zinc fingers of the C2H2-type at the carboxyl-terminus which are highly homologous to the zinc finger regions of the 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 EGR1, EGR2, and pAT 133. In contrast to 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
, in fibroblasts PILOT 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 requires only one signal ( PMA ) and is not affected by CyA. This observation directly demonstrates the existence of a Ca2+ signal-dependent 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 obligatory for expression of some genes in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 but not in fibroblasts. This differential expression model will be valuable in the dissection of the dual signal pathway in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 and the effects of CyA upon it. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D93204975">93204975</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 of human zeta 2 
<mark class="entity" style="background: #BEECAC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin promoter
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">253</span>
</mark>
 by the alpha globin 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 ( HS-40 ) : functional role of specific 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
-DNA complexes. We studied the functional interaction between human embryonic zeta 2 
<mark class="entity" style="background: #BEECAC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin promoter
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">253</span>
</mark>
 and the alpha globin 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 ( HS-40 ) located 40 kb upstream of the zeta 2 
<mark class="entity" style="background: #EF9C99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin gene
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">248</span>
</mark>
. It was shown by 
<mark class="entity" style="background: #EA9DCC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transient expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">224</span>
</mark>
 assay that HS-40 behaved as an authentic enhancer for high-level zeta 2 
<mark class="entity" style="background: #BEECAC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin promoter
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">253</span>
</mark>
 activity in K562 cells, an 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 line of embryonic and / or fetal origin. Although sequences located between -559 and -88 of the zeta 2 
<mark class="entity" style="background: #EF9C99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin gene
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">248</span>
</mark>
 were dispensable for its expression on enhancerless plasmids, they were required for the HS-40 enhancer-mediated activity of the zeta 2 
<mark class="entity" style="background: #BEECAC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin promoter
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">253</span>
</mark>
. Site-directed mutagenesis demonstrated that this HS-40 enhancer-zeta 2 
<mark class="entity" style="background: #BEECAC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin promoter
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">253</span>
</mark>
 interaction is mediated by the two GATA-1 factor binding motifs located at -230 and -104, respectively. The functional domains of HS-40 were also mapped. Bal 31 deletion mapping data suggested that one GATA-1 motif, one GT motif, and two NF-E2 / AP1 motifs together formed the functional core of HS-40 in the erythroid-specific activation of the zeta 2 
<mark class="entity" style="background: #BEECAC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin promoter
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">253</span>
</mark>
. Site-directed mutagenesis further demonstrated that the enhancer function of one of the two NF-E2 / AP1 motifs of HS-40 is mediated through its binding to NF-E2 but not AP1 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
. Finally, we did genomic footprinting of the HS-40 enhancer region in K562 cells, adult nucleated erythroblasts, and different 
<mark class="entity" style="background: #99FFEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonerythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">137</span>
</mark>
. All sequence motifs within the functional core of HS-40, as mapped by 
<mark class="entity" style="background: #EA9DCC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transient expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">224</span>
</mark>
 analysis, appeared to bind a 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 ( s ) in living K562 cells but not in 
<mark class="entity" style="background: #99FFEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonerythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">137</span>
</mark>
. On the other hand, only one of the apparently nonfunctional sequence motifs was bound with factors in vivo. In comparison to K562, nucleated erythroblasts from adult human bone marrow exhibited a similar but nonidentical pattern of 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 binding in vivo at the HS-40 region. These data suggest that 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 of human embryonic zeta 2 
<mark class="entity" style="background: #EF9C99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin gene
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">248</span>
</mark>
 and the fetal / adult alpha globin genes is mediated by 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
-specific and developmental stage-specific 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
-DNA complexes which form at the enhancer ( HS-40 ) and the 
<mark class="entity" style="background: #BEECAC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    globin promoters
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">253</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D93321228">93321228</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Costimulation of cAMP and 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein kinase C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 pathways inhibits the CD3-dependent 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 and leads to a persistent expression of the AP-1 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
. The effects mediated by a combined stimulation of cAMP -and 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein kinase C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 ( 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 ) -dependent pathways have been investigated in different cellular systems, and it has been shown that they may complement each other in activating cell proliferation and differentiation. In this report, we show that upon the stimulation of both pathways 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 became refractory to activation via the CD3 / 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 ( 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 ) complex. 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 preincubated with phorbol 12-myristate 13-acetate ( PMA ) and dibutyryl cAMP ( Bt2cAMP ) displayed a deficient proliferative ability in response to anti-CD3 mAb stimulation, whereas lymphocytes treated individually with either Bt2cAMP or PMA responded comparably to untreated samples. We detected an association between the reduced mitogenic response and low expression of both interleukin-2 ( IL-2 ) and the alpha chain ( CD25 ) of the IL-2 receptor ( IL-2R ) . Analysis of intracellular Ca2+ mobilization suggested that the CD3 / 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
-dependent signal transduction was impaired in PMA / Bt2cAMP-treated cells. Remarkably, we observed that these samples displayed a persistent expression of the c-fos protooncogene, associated to an increased AP-1 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity, whereas no variations of CREB or NF-kB were detected. Neither Bt2cAMP nor PMA individually mediated these sustained effects, which therefore appear as a consequence of the interplay between both metabolic stimuli. Altogether, the data provide the evidence that both pathways complement each other in regulating 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 and, conversely, downregulate the 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TcR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 transduction mechanisms. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D94085904">94085904</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Transient pseudohypoaldosteronism in obstructive renal disease with transient reduction of lymphocytic aldosterone receptors. Results in two affected infants. We report two patients with transient pseudohypoaldosteronism due to obstructive renal disease. Both patients presented with a salt-losing episode simulating adrenal insufficiency. In one patient, transient reduction of aldosterone receptors could be documented, while in the second patient the clinical and biochemical parameters were consistent with transient pseudohypoaldosteronism. Aldosterone receptors were normal in both patients </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D94107268">94107268</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Induction of 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 and 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 by vanadate peroxide, an inhibitor of protein tyrosine phosphatases. Rapid 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of key cellular proteins is a crucial event in the transduction of activation signals to 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. The regulatory role of protein tyrosine phosphatases ( PTPases ) in this process was explored by studying the effects of a powerful PTPase inhibitor, vanadate peroxide ( pervanadate ) , on the activation cascade of Jurkat human leukaemic 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Pervanadate induced activation of the 
<mark class="entity" style="background: #E9ACFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine kinases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">291</span>
</mark>
 lck and fyn ( 4- and 3-fold respectively ) and a dramatic increase in 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of cellular proteins, notably phospholipase C gamma 1. After this event, we observed a rise in intracellular Ca2+ concentration, corresponding to an influx. This effect required surface expression of the CD45 PTPase and was not observed in CD45-deficient variants of 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
. In the CD45-negative variant, the effect of pervanadate on 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 was globally decreased and some phosphorylated substrates were specifically missing. Pervanadate also stimulated transcription of the c-fos gene and accumulation of its mRNA as well as several other hallmarks of 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-lymphocyte
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 activation such as surface expression of the CD69 antigen and the interleukin 2 
<mark class="entity" style="background: #BFB9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    receptor alpha-chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">45</span>
</mark>
 ( CD25 ) . Pervanadate synergized with signals delivered by T-cell antigen receptor engagement or by a 
<mark class="entity" style="background: #BDBDEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phorbol ester
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">215</span>
</mark>
 to induce interleukin 2 production. Pervanadate activated 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
, as shown by an increase in 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity of this 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
. We thus conclude that PTPases play a crucial role in the negative regulation of signal transduction culminating in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-lymphocyte
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 activation. Moreover, induction of 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 appears sufficient per 
<mark class="entity" style="background: #CABEF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    se
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">212</span>
</mark>
 to initiate a complete activation programme. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D94209654">94209654</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Activation of a novel serine / 
<mark class="entity" style="background: #CCEEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    threonine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">290</span>
</mark>
 that phosphorylates c-Fos upon stimulation of T and B lymphocytes via antigen and cytokine receptors. Ligation of Ag receptors in T and B lymphocytes initiates signal transduction cascades which alter the 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    expression of genes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 that regulate 
<mark class="entity" style="background: #9FCCAB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cellular proliferation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">150</span>
</mark>
 and differentiation. The transmission of signals from the membrane to the nucleus is mediated principally through the action of protein tyrosine and serine / 
<mark class="entity" style="background: #CCEEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    threonine kinases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">290</span>
</mark>
. We have identified and characterized a novel serine / 
<mark class="entity" style="background: #CCEEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    threonine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">290</span>
</mark>
 that phosphorylated the proto-oncogene product, c-Fos, and is termed 
<mark class="entity" style="background: #BBDFDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fos kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">242</span>
</mark>
. 
<mark class="entity" style="background: #BBDFDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fos kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">242</span>
</mark>
 was rapidly activated after ligation of the CD3 and CD2 receptors in Jurkat and normal human 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 and in response to IL-6 and anti-IgM in the human B 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 AF10 and Ramos, respectively. The 
<mark class="entity" style="background: #BDBDEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phorbol ester
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">215</span>
</mark>
, PMA, was also a potent inducer of 
<mark class="entity" style="background: #BBDFDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fos kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">242</span>
</mark>
 activity in all of the above populations, suggesting that 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 plays a role in the regulation of this enzyme. 
<mark class="entity" style="background: #BBDFDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fos kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">242</span>
</mark>
 phosphorylates c-Fos at a site near the C-terminus, as well as a peptide derived from this region ( residues 359-370, RKGSSSNEPSSD ) , and Fos peptide competitively inhibited c-Fos phosphorylation. 
<mark class="entity" style="background: #BBDFDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fos kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">242</span>
</mark>
 was shown to be distinct from other identified serine / 
<mark class="entity" style="background: #CCEEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    threonine kinases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">290</span>
</mark>
, including protein kinase A, 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein kinase C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
, 
<mark class="entity" style="background: #B9CBFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    casein kinase II
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">104</span>
</mark>
, MAP kinases, p70S6K and p90RSK. 
<mark class="entity" style="background: #BBDFDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fos kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">242</span>
</mark>
 was purified by anion exchange chromatography and exhibited an apparent M ( r ) = 65,000 and isoelectric point = 6.1. 
<mark class="entity" style="background: #BBDFDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Fos kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">242</span>
</mark>
 may play a role in transcriptional regulation through its capacity to phosphorylate c-Fos at a site required for expression of the transcriptional transrepressive activity of this molecule. Moreover, its rapid activation suggests it may have a wider role within signal transduction cascades in lymphocytes. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D94238882">94238882</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Induction of proto-oncogene and cytokine expression in human 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
 and the monocytic 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 THP-1 after stimulation with mycoplasma-derived material MDHM. Mycoplasma fermentans-derived high-molecular-weight material ( MDHM ) was originally described to induce differentiation of murine thymocytes to cytolytic effector 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 by stimulating IL-6 release from adherent cells. This study shows that human 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
 ( 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBMo
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
 ) also respond to MDHM with increases in IL-1 beta, IL-6 and 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 expression, both at the mRNA and protein level. The 
<mark class="entity" style="background: #C99BDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    induced expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">220</span>
</mark>
 of IL-1 beta and 
<mark class="entity" style="background: #EEEDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF alpha mRNA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">49</span>
</mark>
 in the monocytic THP-1 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 increased as quickly as in primary cells. In contrast to 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBMo
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
, THP-1 and 14 other monocytic / myeloid leukemia-derived 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 did not secrete measurable amounts of the cytokines upon treatment with MDHM. IL-1 beta and IL-6 genes contain AP-1 binding sites as 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
, the AP-1 protein being composed of c-jun and c-fos gene products. In 
<mark class="entity" style="background: #CEFDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    THP-1 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">145</span>
</mark>
 c-jun mRNA expression increased after incubation with MDHM while positive c-fos expression remained unaffected. Although these data suggest AP-1 regulated cytokine mRNA expression, results from 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBMo
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
 are not in accordance with this notion. In the primary cells MDHM-induced elevation of cytokine mRNA levels was preceded by a downregulation of c-fos expression while positive c-jun expression was not modulated. c-myc mRNA expression, constitutively high in 
<mark class="entity" style="background: #CEFDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    THP-1 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">145</span>
</mark>
, was induced in MDHM-stimulated 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBMo
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
. In conclusion, MDHM-stimulated induction of cytokine mRNA expression was accompanied by different proto-oncogene responses in 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PBMo
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
 and 
<mark class="entity" style="background: #CEFDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    THP-1 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">145</span>
</mark>
. These differences may represent different regulatory pathways of the two cell systems. Alternatively, these data support the notion that neither AP-1 nor the c-myc protein are involved in the MDHM-induced increase in IL-1 beta, IL-6 or 
<mark class="entity" style="background: #EEEDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF alpha mRNA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">49</span>
</mark>
 levels. Furthermore, the present results demonstrate clearly that mycoplasma products can have a profound impact on the activation status of eukaryotic cells. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D94254835">94254835</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Lipopolysaccharide induction of 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tissue factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
 is mediated by binding of c-Rel / 
<mark class="entity" style="background: #AEEAFE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    p65 heterodimers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">258</span>
</mark>
 to a 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B-like site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
. Exposure of 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
 to bacterial lipopolysaccharide ( LPS ) activates the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 / Rel family of proteins and leads to the rapid induction of inflammatory gene products, including 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tissue factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 ( 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 ) . 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 is the primary cellular initiator of the coagulation protease cascades. Here we report the characterization of a nuclear complex from human 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
 that bound to a 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B-like site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
, 5'--3', in the 5'-flanking region of the human 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 gene. This nuclear complex was activated by LPS with kinetics that preceded induction of the 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 gene. In vitro binding studies demonstrated that the 
<mark class="entity" style="background: #FFAAEA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">235</span>
</mark>
 bound translated c-Rel and p65 homodimers but not p50 / 
<mark class="entity" style="background: #AEEAFE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    p65 heterodimers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">258</span>
</mark>
 or p50 homodimers. Base-pair substitutions in the 
<mark class="entity" style="background: #FFAAEA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">235</span>
</mark>
 indicated that the presence of a cytosine at position 1 precluded binding of NF-kappa B. In fact, under low-ionic-strength conditions, the 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 complex did not migrate with translated p50 / p65 dimers but instead comigrated with c-Rel / p65 dimers. Antibodies against the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 and 
<mark class="entity" style="background: #9DCCAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rel proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">309</span>
</mark>
 and UV cross-linking studies revealed the presence of c-Rel and p65 and the absence of p50 in the 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 complex and further showed that c-Rel / 
<mark class="entity" style="background: #AEEAFE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    p65 heterodimers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">258</span>
</mark>
 selectively bound to the 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B-like site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
. Functional studies indicated that the 
<mark class="entity" style="background: #FFAAEA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">235</span>
</mark>
 conferred LPS inducibility on a heterologous promoter and was transactivated by c-Rel or p65. Taken together, our results demonstrated that binding of c-Rel / 
<mark class="entity" style="background: #AEEAFE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    p65 heterodimers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">258</span>
</mark>
 to a novel 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B-like site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
 mediated LPS induction of 
<mark class="entity" style="background: #FCF9CF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">236</span>
</mark>
 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95000924">95000924</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Role of HIV-1 Nef expression in activation pathways in CD4+ 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. The role of the 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human immunodeficiency virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 ( HIV-1 ) Nef protein in 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 pathways was investigated using a Jurkat CD4+ 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 stably transfected with a Nef expression vector. Secretion of IL-2 and 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
, surface expression of IL-2R, and 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activity of NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and AP-1 ( Fos / Jun ) complex in response to 
<mark class="entity" style="background: #EF9DBE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phorbol myristate acetate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">4</span>
</mark>
, 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
, or immobilized antibodies to CD3 were monitored. These parameters were not modified by Nef expression in 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
, whereas stimulation with the same stimuli resulted in partial inhibition of LTR activation in Nef+ 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
. This inhibition was not mediated through Nef phosphorylation on Thr-15 or GTP-binding activity because mutations in critical sites did not alter this inhibition. Analysis of truncated LTRs confirmed that inhibition of LTR activation was not mediated through 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
-binding activity but through the region containing the negative responding elements ( NREs ) . These results suggest that Nef downmodulates LTR activation without significantly inhibiting the capacity of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 to respond to immunological activations. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95036290">95036290</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Distinct DNase-I 
<mark class="entity" style="background: #99FCB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersensitive sites
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">273</span>
</mark>
 are associated with TAL-1 transcription in erythroid and 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
. The tal-1 gene, frequently activated in human T-cell acute lymphoblastic leukemia ( T-ALL ) , is expressed in the erythroid, megakaryocytic, and mast cell lineages during normal hematopoiesis. To gain further insight into the molecular mechanisms that control tal-1 expression, we investigated tal-1 chromatin structure in erythroid / megakaryocytic 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 and in 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
 either with or without tal-1 rearrangements. Tal-1 transcription was shown to be monoallelic in Jurkat, a 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
 that expresses tal-1 in the absence of apparent genomic alteration of the locus. Methylation studies indicated that the tal-15' GC-rich region behaves like a CpG island, hypomethylated in normal cells, and methylated de novo on transcriptionally inactive alleles in established 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
. Five major DNase-I 
<mark class="entity" style="background: #99FCB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersensitive sites
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">273</span>
</mark>
 ( 
<mark class="entity" style="background: #99FCB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">273</span>
</mark>
 ) were mapped in the tal-1 locus. 
<mark class="entity" style="background: #99FCB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">273</span>
</mark>
 I, IV, and V were exclusively observed in the erythroid / megakaryocytic 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 that express tal-1 from the promoters 1a and 1b. 
<mark class="entity" style="background: #99FCB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">273</span>
</mark>
 II was weak in hematopoietic 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
, absent in Hela, and greatly enhanced in Jurkat, suggesting that this region might be implicated in the cis-activation of tal-1 promoter 1b in this 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
. 
<mark class="entity" style="background: #99FCB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">273</span>
</mark>
 III was weak in HEL and Jurkat, and greatly enhanced in DU528, a 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
 that bears a t ( 1;14 ) and initiates tal-1 transcription within exon 4. These results suggest that distinct 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 are associated with the use of the different tal-1 promoters. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95065655">95065655</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epstein-Barr virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 SM protein. The protein products of the 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epstein-Barr virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 ( 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 ) BMLF1 open reading frame have been characterized in the early productive cycle in B95-8 and Akata cells. The SM protein derived from the spliced RNA joining BSLF2 to BMLF1 is much the most abundant protein. SM is a phosphoprotein in 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
-infected cells and can be phosphorylated in vitro with 
<mark class="entity" style="background: #B9CBFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    casein kinase II
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">104</span>
</mark>
 ( 
<mark class="entity" style="background: #B9CBFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CKII
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">104</span>
</mark>
 ) . Computer analysis of the SM protein sequence showed a C terminal section of SM to be related to genome positional homologues of four other herpesviruses and revealed consensus 
<mark class="entity" style="background: #B9CBFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CKII
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">104</span>
</mark>
 sites near the N termini of the 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 SM protein, the herpes simplex virus ( HSV ) ICP27 protein and the herpesvirus saimiri ( HVS ) open reading frame 57 protein. Site-directed mutagenesis of the consensus 
<mark class="entity" style="background: #B9CBFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CKII
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">104</span>
</mark>
 site in 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 SM greatly reduced the in vitro phosphorylation of SM by 
<mark class="entity" style="background: #B9CBFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CKII
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">104</span>
</mark>
. The mechanism of transactivation by BMLF1 proteins has been controversial but SM was shown to transactivate 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 from a CAT reporter construct by increasing the amount of cytoplasmic CAT mRNA. Mutagenesis of the 
<mark class="entity" style="background: #B9CBFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CKII
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">104</span>
</mark>
 site in SM made no difference to the transactivation in this transient transfection assay. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95127261">95127261</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Alternate 
<mark class="entity" style="background: #9AF9D9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    immune system
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">277</span>
</mark>
 targets for TCDD: lymphocyte stem cells and extrathymic T-cell development. We here summarize evidence that thymic atrophy induced by 2,3,7,8-tetrachlorodibenzo-p-dioxin ( TCDD ) can be mediated, at least in part, by damage to extrathymic T-cell precursors in bone marrow and fetal liver. This atrophy induction does not involve apoptotic mechanisms in thymocytes affected by the bcl-2 proto-oncogene. TCDD mediates atrophy induction through its specific receptor ( the AhR ) and not through effects on the 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    estrogen receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
. Both TCDD and estradiol induce extrathymic T-cell differentiation in the liver. These extrathymic T-cell populations include cells expressing elevated levels of V beta T-cell receptors that are normally deleted in thymic development. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95166251">95166251</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Expression of the Runt domain-encoding PEBP2 alpha genes in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 during thymic development. The PEBP2 alpha A and 
<mark class="entity" style="background: #DDEDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PEBP2 alpha B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">41</span>
</mark>
 genes encode the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 subunit of a murine 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
, PEBP2, which is implicated as a T-cell-specific transcriptional regulator. These two related genes share the evolutionarily conserved region encoding the Runt domain. 
<mark class="entity" style="background: #DDEDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PEBP2 alpha B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">41</span>
</mark>
 is the murine counterpart of human AML1, which is located at the breakpoints of the 8;21 and 3;21 chromosome translocations associated with acute myeloid leukemia. Northern ( RNA ) blots of various adult mouse tissues revealed that the levels of expression of both genes were most prominent in the thymus. Furthermore, transcripts of PEBP2 alpha A and mouse AML1 / 
<mark class="entity" style="background: #DDEDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PEBP2 alpha B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">41</span>
</mark>
 were detected in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 in the thymuses from day 16 embryos and newborns, as well as 4-week-old adult mice, by in situ hybridization. The expression of the genes persisted in peripheral lymph nodes of adult mice. The transcripts were detected in all the CD4- CD8-, CD4+ CD8+, CD4+ CD8-, and CD4- CD8+ cell populations. The results indicated that both genes are expressed in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 throughout their development, supporting the notion that PEBP2 is a 
<mark class="entity" style="background: #9CAEC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell-specific transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">121</span>
</mark>
. Transcripts of mouse AML1 / 
<mark class="entity" style="background: #DDEDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PEBP2 alpha B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">41</span>
</mark>
 were also detected in day 12 fetal hematopoietic liver and in the bone marrow cells of newborn mice. The implication of mouse AML1 / 
<mark class="entity" style="background: #DDEDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PEBP2 alpha B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">41</span>
</mark>
 expression in hematopoietic cells other than those of T-cell lineage is discussed in relation to myeloid leukemogenesis. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95202809">95202809</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Aspirin inhibits 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 mobilization and monocyte adhesion in stimulated human 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
. BACKGROUND: The 
<mark class="entity" style="background: #ACFCAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    induction of vascular cell adhesion molecule-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">36</span>
</mark>
 ( 
<mark class="entity" style="background: #DFEEDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    VCAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">37</span>
</mark>
 ) and E-selectin by 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ( 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ) is mediated by mobilization of the 
<mark class="entity" style="background: #AEBAAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">77</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) . Since salicylates have been reported to inhibit 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 by preventing the degradation of its inhibitor I kappa B, we studied a potential inhibition of this pathway by acetylsalicylate ( aspirin ) in 
<mark class="entity" style="background: #CCCEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human umbilical vein endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">116</span>
</mark>
 ( 
<mark class="entity" style="background: #CCCEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HUVECs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">116</span>
</mark>
 ) . METHODS AND RESULTS: Gel-shift analyses demonstrated dose-dependent inhibition of 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
-induced 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 mobilization by aspirin at concentrations ranging from 1 to 10 mmol / L. 
<mark class="entity" style="background: #ACFCAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Induction of VCAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">36</span>
</mark>
 and E-selectin surface expression by 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 was dose-dependently reduced by aspirin over the same range, while induction of 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intercellular adhesion molecule-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 ( 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 ) was hardly affected. Aspirin appeared to prevent 
<mark class="entity" style="background: #DFEEDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    VCAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">37</span>
</mark>
 transcription, since it dose-dependently inhibited 
<mark class="entity" style="background: #ACFCAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    induction of VCAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">36</span>
</mark>
 mRNA by 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
. As a functional consequence, adhesion of U937 monocytes to 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
-stimulated 
<mark class="entity" style="background: #CCCEFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HUVECs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">116</span>
</mark>
 was markedly reduced by aspirin due to suppression of 
<mark class="entity" style="background: #DFEEDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    VCAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">37</span>
</mark>
 and E-selectin upregulation. These effects of aspirin were not related to the inhibition of cyclooxygenase activity, since indomethacin was ineffective. CONCLUSIONS: Our data suggest that aspirin inhibits 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 mobilization, 
<mark class="entity" style="background: #ACFCAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    induction of VCAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">36</span>
</mark>
 and E-selectin, and subsequent monocyte adhesion in 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
 stimulated by 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
, thereby providing an additional mechanism for therapeutic effects of aspirin. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95222739">95222739</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transcriptional activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 of core binding factor-alpha ( AML1 ) and beta subunits on murine leukemia virus enhancer cores. Core binding factor ( CBF ) , also known as polyomavirus enhancer-binding protein 2 and SL3 enhancer factor 1, is a mammalian 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 that binds to an element termed the core within the enhancers of the murine leukemia virus family of retroviruses. The core elements of the SL3 virus are important genetic determinants of the ability of this virus to induce T-cell lymphomas and the 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 of the viral long terminal repeat in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. CBF consists of two subunits, a 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 subunit, 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CBF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
, and a second subunit, CBF beta, that stimulates the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity of 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CBF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
. One of the genes that encodes a 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CBF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
 subunit is AML1, also called 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cbf alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
 2. This locus is rearranged by chromosomal translocations in human myeloproliferative disorders and leukemias. An exogenously expressed 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Cbf alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
 2-encoded subunit ( 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CBF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
 2-451 ) stimulated transcription from the SL3 enhancer in P19 and HeLa cells. Activity was mediated through the core elements. Three different isoforms of CBF beta were also tested for 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 on the SL3 enhancer. The longest form, CBF beta-187, increased the transcriptional stimulation by 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CBF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
 2-451 twofold in HeLa cells, although it had no effect in P19 cells. 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 by CBF beta required binding to the 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CBF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
 subunit, as a form of CBF beta that lacked binding ability, CBF beta-148, failed to increase activity. These results indicated that at least in certain cell types, the maximum activity of CBF required both subunits. They also provided support for the hypothesis that CBF is a factor in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 that is responsible for recognition of the SL3 cores. We also examined whether CBF could distinguish a 1-bp difference between the enhancer core of SL3 and the core of the nonleukemogenic virus, Akv. This difference strongly affects transcription in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 and leukemogenicity of SL3. However, no combination of 
<mark class="entity" style="background: #BEBEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CBF alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">42</span>
</mark>
 and CBF beta subunits that we tested was able to distinguish the 1-bp difference in transcription assays. Thus, a complete understanding of how 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 recognize the SL3 core remains to be elucidated. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95261059">95261059</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Neutrophils and monocytes express high levels of PU.1 ( Spi-1 ) but not Spi-B. PU.1 ( the Spi-1 oncogene ) and Spi-B are closely related members of the ets 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 family, sharing similar 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 specificities mediated by similar 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 domains. PU.1 and Spi-B have been previously described as being predominantly expressed coordinately in macrophages and 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
, but their expression in early hematopoietic stages and during the course of myeloid differentiation to monocytes and macrophages or to neutrophils has not been extensively investigated. Here, we report that PU.1 mRNA is upregulated during myeloid differentiation of human purified CD34+ cells and murine multipotential FDCP-mix A4 cells, suggesting that PU.1 is upregulated as an early event during differentiation of multipotential progenitor cells. PU.1 expression is maintained at stable levels during differentiation of myeloid 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 U937 and HL-60 to monocytic and neutrophilic cells. PU.1 is expressed at highest levels in mature 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 and human 
<mark class="entity" style="background: #BBEFAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">97</span>
</mark>
 neutrophils. In contrast to PU.1, significant levels of Spi-B mRNA and protein are found only in some B-
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 and spleen but are not found in myeloid 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
, neutrophils, or macrophages. In vitro translated Spi-B protein can bind to PU.1 binding sites in myeloid promoters and transactivate these promoters in nonmyeloid cells. Therefore, although PU.1 and Spi-B may bind to similar DNA control elements and have redundancy of transactivation function in vitro, the lack of significant levels of Spi-B in myeloid cells makes it unlikely that Spi-B plays a significant role in myeloid lineage development and 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
. In contrast, PU.1 is expressed at high levels not only in monocytes and macrophages but also in neutrophils, indicating that PU.1 can activate 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in both major myeloid lineages. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95332324">95332324</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Integrin-mediated 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 and cytokine message induction in 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
. A possible signaling role for the 
<mark class="entity" style="background: #ADAB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Syk tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">289</span>
</mark>
. Activation of cytoplasmic 
<mark class="entity" style="background: #E9ACFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine kinases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">291</span>
</mark>
 is an important aspect of signal transduction mediated by integrins. In the human monocytic 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 THP-1, either integrin-dependent cell adhesion to fibronectin or ligation of beta 1 integrins with antibodies causes a rapid and intense 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of two sets of proteins of about 65-75 and 120-125 kDa. In addition, integrin ligation leads to 
<mark class="entity" style="background: #9EEF9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear translocation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">304</span>
</mark>
 of the p50 and p65 subunits of the 
<mark class="entity" style="background: #AEBAAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">77</span>
</mark>
, to activation of a reporter gene driven by a promoter containing 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 sites, and to increased levels of mRNAs for immediate-early genes, including the cytokine interleukin ( IL ) -1 beta. The 
<mark class="entity" style="background: #E9ACFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">291</span>
</mark>
 inhibitors genistein and herbimycin A block both integrin-mediated 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 and increases in IL-1 beta message levels, indicating a causal relationship between the two events. The components tyrosine phosphorylated subsequent to cell adhesion include paxillin, pp125FAK, and the SH2 domain containing 
<mark class="entity" style="background: #ADAB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine kinase Syk
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">289</span>
</mark>
. In contrast, integrin ligation with antibodies induces 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of Syk but not of FAK or paxillin. In adhering cells, pre-treatment with cytochalasin D suppresses 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of FAK and paxillin but not of Syk, while IL-1 beta message induction is unaffected. These observations indicate that the 
<mark class="entity" style="background: #ADAB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Syk tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">289</span>
</mark>
 may be an important component of an integrin signaling pathway in 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
, leading to 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and to increased levels of cytokine messages. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D95399771">95399771</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Regulation of 
<mark class="entity" style="background: #9CFEBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    granulocyte-macrophage colony
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">161</span>
</mark>
-stimulating factor and E-selectin expression in 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
 by cyclosporin A and the T-cell 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 NFAT. 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 ( NFAT ) was originally described as a 
<mark class="entity" style="background: #9CAEC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell-specific transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">121</span>
</mark>
 athat supported the activation of cytokine 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 and mediated the immunoregulatory effects of cyclosporin A ( CsA ) . As we observed that activated 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
 also expressed NFAT, we tested the antiinflammatory properties of CsA in 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
. Significantly, CsA completely suppressed the induction of NFAT in 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
 and inhibited the activity of 
<mark class="entity" style="background: #9CFEBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    granulocyte-macrophage colony
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">161</span>
</mark>
-stimulating factor ( 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 ) gene 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 that use NFAT by 60%. CsA similarly mediated a reduction of up to 65% in 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 mRNA and protein expression in activated 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
. CsA also suppressed E-selectin, but not 
<mark class="entity" style="background: #DFEEDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    vascular cell adhesion molecule-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">37</span>
</mark>
 ( 
<mark class="entity" style="background: #DFEEDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    VCAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">37</span>
</mark>
 ) expression in 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
, even though the E-selectin promoter is activated by 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 rather than NFAT. Hence, induction of cell surface expression of this leukocyte adhesion molecule by 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ( 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ) -alpha was reduced by 40% in the presence of CsA, and this was reflected by a 29% decrease in neutrophil adhesion. The effects of CsA on 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
 were also detected at the chromatin structure level, as DNasel 
<mark class="entity" style="background: #99FCB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    hypersensitive sites
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">273</span>
</mark>
 within both the 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 enhancer and the E-selectin promoter were suppressed by CsA. This represents the first report of NFAT in 
<mark class="entity" style="background: #AFBB9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    endothelial cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">115</span>
</mark>
 and suggests mechanisms by which CsA could function as an antiinflammatory agent. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96038813">96038813</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Cloning a cDNA from human NK / 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 which codes for a protein with high proline content. A cDNA clone, B4-2, was isolated from a natural killer ( NK ) minus T cell subtractive library. The B4-2 clone coded for an mRNA of 2061 bp in length. It encodes a deduced 327 aa protein with a calculated molecular mass of 35.2 kDa. Searching of B4-2 DNA and protein sequences against various databases revealed no high homology to other sequences. However, B4-2 has an unusually high proline content ( 13% ) , contains a putative nuclear targeting sequence, and has several SPXX motifs which are frequently found in gene regulatory proteins. One of the stretches of prolines in B4-2 closely resembles the ligand for proteins with SH3 domains. Northern hybridization data showed that B4-2 is not a lymphoid specific gene and is expressed in a hepatoma 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 and also weakly transcribed or absent in a variety of other cells. A polyclonal antiserum raised against recombinant B4-2 recognizes a 32-34 kDa protein in lymphocytes. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96074632">96074632</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Down-regulation of 
<mark class="entity" style="background: #BCFEDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B protein
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">76</span>
</mark>
 levels in activated human lymphocytes by 1,25-
<mark class="entity" style="background: #A9BCFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dihydroxyvitamin D3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">187</span>
</mark>
 [published erratum appears in Proc Natl Acad Sci U S A 1996 Jan 9;93 ( 1 ) :524] The effect of 1,25-
<mark class="entity" style="background: #A9BCFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dihydroxyvitamin D3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">187</span>
</mark>
 [1,25 ( OH ) 2 ) D3], a steroid hormone with immunomodulating properties, on 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) proteins was examined in in vitro activated normal human lymphocytes by Western blot analysis. Over a 72-hr period of activation, the expression of the 50-kDa 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
, p50, and its precursor, p105, was increased progressively. When cells were activated in the presence of 1,25 ( OH ) 2D3, the levels of the mature protein as well as its precursor were decreased. The effect of the hormone on the levels of p50 was demonstrable in the cytosolic and 
<mark class="entity" style="background: #C9AABC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear compartments
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">163</span>
</mark>
; it required between 4 and 8 hr and was specific, as 25-hydroxyvitamin D3 and 24,25-
<mark class="entity" style="background: #A9BCFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dihydroxyvitamin D3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">187</span>
</mark>
 were ineffective. Besides p50, 1,25 ( OH ) 2D3 decreased the levels of another 
<mark class="entity" style="background: #BCFEDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B protein
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">76</span>
</mark>
, namely c-rel. In addition, 1,25 ( OH ) 2D3 decreased the abundance of a specific DNA-protein complex formed upon incubation of 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 from activated lymphocytes with a labeled 
<mark class="entity" style="background: #ACF9FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">69</span>
</mark>
 motif. Further, 1,25 ( OH ) 2D3 inhibited the 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 of NF-kappa B in 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
 transiently transfected with a construct containing four tandem repeats of the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 binding sequence of the immunoglobulin kappa light chain gene linked to the chloramphenicol acetyltransferase reporter gene. These observations demonstrate directly that there is de novo synthesis of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 during human lymphocyte activation and suggest that this process is hormonally regulated. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96075792">96075792</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 priming of monocytes enhances LPS-induced 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 production by augmenting both transcription and MRNA stability. The induction of cytokine expression in monocytes / macrophages by bacterial endotoxin or lipopolysaccharide is a critical, highly regulated host defence response. The augmentation of LPS responses by 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    interferon gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 ( 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 ) , referred to as priming, is well established. However, the mechanism ( s ) by which priming occurs is poorly defined. Using 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumour necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ( 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ) induction as a model, experiments were designed to analyse in detail the priming effect on the LPS response in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. Priming by 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 was primarily manifested at the level of 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 mRNA accumulation. 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 pre-treatment affected the magnitude rather than the sensitivity of the LPS response. Priming occurred after several hours of treatment, and the primed state was induced by either 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 or 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
, but not M-CSF. Primed monocytes transcribed 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 mRNA at a higher rate than freshly isolated monocytes upon activation with LPS. The increased transcriptional rate correlated with a marked increase in 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 in these cells as determined by 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assay
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 using a consensus 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 oligonucleotide. An additional significant finding was than 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 mRNA induced in primed cells was much more stable than in unprimed cells ( T1 / 2 increased 6-8-fold ) . Consistent with the increased mRNA stability, the duration of mRNA accumulation was longer following 
<mark class="entity" style="background: #AAFAAB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    LPS stimulation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">295</span>
</mark>
 in primed monocytes, in addition to being of greater magnitude. Finally, primed and unprimed cells possessed a differential sensitivity to the kinase inhibitor H-89. H-89 substantially suppressed LPS-induced 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 mRNA accumulation in unprimed cells, but had no effect on primed monocytes following 
<mark class="entity" style="background: #AAFAAB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    LPS stimulation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">295</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96079922">96079922</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Prolactin and interleukin-2 receptors in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 signal through a MGF-STAT5-like 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
. The cell surface receptors for PRL and interleukin-2 ( IL-2 ) are structurally distinct, but share regulatory tasks in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. They can stimulate proliferation and activate transcription of over-lapping sets of genes of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. PRL and IL-2 receptor activation are both linked to the Jak / Stat ( 
<mark class="entity" style="background: #BCAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    signal transducer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">320</span>
</mark>
 and 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activator of transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 ) pathway. We investigated the ability of PRL and IL-2 to activate 
<mark class="entity" style="background: #BC99FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Stat proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">310</span>
</mark>
 in different 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
. The 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 specificities, the reactivities toward Stat-specific antisera, and the mol wt of IL-2 -and PRL-induced 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 proteins in Nb2 and C196 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
 were investigated. A comparison with the 
<mark class="entity" style="background: #BC99FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Stat proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">310</span>
</mark>
 induced by 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    interferon-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
, PRL, and IL-6 in T47D mammary tumor cells was made. We found that these parameters were indistinguishable for one of the PRL- and IL-2-induced factors. A 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 closely related to mammary gland factor-Stat5 is rapidly activated upon interaction of IL-2 and PRL with their respective receptors. Activation of a second protein related to Stat1 was also observed. Our results emphasize the role of PRL as a regulator of the immune response and indicate that the Stat factors mammary gland factor-Stat5 and Stat1 play a role in the regulation of 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 during T cell development. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96085174">96085174</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Interleukin-7 can induce the activation of Jak 1, Jak 3 and STAT 5 proteins in murine 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. The activation of Janus 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 ( Jak ) and STAT ( 
<mark class="entity" style="background: #BCAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    signal transducer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">320</span>
</mark>
 and 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activator of transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 ) proteins has recently been linked to the signal transduction mechanism of several cytokines. IL-7 was observed to induce a rapid and dose-dependent 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of Jak 1 and Jak 3 and concomitantly, the 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 and 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity of multiple 
<mark class="entity" style="background: #BC99FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    STAT proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">310</span>
</mark>
. The 
<mark class="entity" style="background: #BC99FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    STAT proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">310</span>
</mark>
 utilized by IL-7 were identical to those induced by IL-2 and could be identified as various STAT 5 isoforms. Moreover, the induction of both Jak 1 and 3, and STAT 5 activity strongly correlated with the growth-promoting effects of IL-7, suggesting that this signal transduction mechanism may play a key role in IL-7-induced proliferation. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96184791">96184791</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Coexpression of the interleukin-13 and interleukin-4 genes correlates with their physical linkage in the cytokine gene cluster on human chromosome 5q23-31. Interleukin-13 ( IL-13 ) and IL-4 are cytokines produced by 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 that are encoded by the q23-31 region of human chromosome 5. To investigate the regulation of IL-13 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 by 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
, we isolated and sequenced the human IL-13 gene, analyzed its 5'-flanking region for potential 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 elements, and examined its expression in nontransformed T-lineage cell populations. The human IL-13 gene was located 12.5-kb upstream of the IL-4 gene and 2-kb downstream of a CpG island. The IL-13 gene 5' flank region included a segment with sequence homology to 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 of the IL-4 promoter involved in 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Mutation of the IL-13 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 site significantly reduced IL-13 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
 in response to 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
. Oligonucleotides containing the IL-13 or IL-4 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 sites specifically bound the 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activator
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 protein, 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
-activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
, preformed ( NF-ATp ) , when incubated with nuclear protein extracts from activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Similar to IL-4, IL-13 mRNA expression was highest in T-cell populations enriched for cells that had previously been primed in vivo or in vitro, indicating that priming increases the expression of the IL-13 and IL-4 genes in a coordinate manner. Because the primed 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 contain higher levels of nuclear NF-ATp, capable of binding to 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 of the IL-4 and IL-13 promoters, than do freshly-isolated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
, the NF-AT-binding 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 are attractive candidates to mediate the coordinate expression of these two cytokine genes. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96185499">96185499</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p [see comments] Trapoxin is a microbially derived cyclotetrapeptide that inhibits histone deacetylation in vivo and causes mammalian cells to arrest in the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
. A trapoxin affinity matrix was used to isolate two nuclear proteins that copurified with histone deacetylase activity. Both proteins were identified by peptide microsequencing, and a 
<mark class="entity" style="background: #DDBDFE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    complementary DNA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">164</span>
</mark>
 encoding the histone deacetylase catalytic subunit ( HD1 ) was cloned from a human Jurkat T cell library. As the predicted protein is very similar to the yeast transcriptional regulator Rpd3p, these results support a role for histone deacetylase as a key regulator of eukaryotic transcription. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96195006">96195006</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">cAMP inducibility of transcriptional repressor ICER in developing and mature human 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 [published erratum appears in Proc Natl Acad Sci U S A 1996 Jul 23;93 ( 15 ) :8154] Stimulation of the cAMP-dependent signaling pathway exerts an inhibitory effect on the proliferation and effector functions of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. The ability of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 to form high intracellular levels of cAMP is acquired during development in the human thymus and is retained by the majority of mature peripheral 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. Here we show that elevated cAMP levels in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 correlate with the expression of the potent transcriptional repressor ICER ( inducible cAMP early repressor ) previously described in the hypothalamic-pituitary-gonadal axis. Further, in transcriptional assays in vivo, ICER inhibits calcineurin-mediated expression of the interleukin 2 promoter as well as Tax-mediated transactivation of the human T-lymphotropic virus type I ( HTLV-I ) promoter. Thus, the induction of ICER in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 may play an important role in the cAMP-induced quiescence and the persistent latency of HTLV-I. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96211859">96211859</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Age-related decreases in IL-2 production by human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 are associated with impaired activation of nuclear 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 AP-1 and NF-AT. Although 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 AP-1 and 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 ( NF-AT ) are important for the normal induction of IL-2, it is unknown if the age-related decline in IL-2 production by activated human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 may be associated with aberrancies in transcriptional regulatory proteins. In the current studies, IL-2 production by 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 from elderly ( mean 78 years ) and young ( mean 37 years ) humans was measured in cultures stimulated with PHA, PHA plus PMA, crosslinked anti-CD3 mAB OKT3 plus PMA, or PMA plus ionomycin. Substantial decreases of IL-2 production were observed for cell cultures from 7 of 12 elderly individuals in response to the different stimuli, whereas the levels of IL-2 produced by stimulated 
<mark class="entity" style="background: #CEEEFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells from other elderly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">114</span>
</mark>
 individuals were equivalent to those observed for stimulated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 of young subjects. Analyses of 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 by electrophoretic DNA mobility shift assays showed that decreased IL-2 production by stimulated 
<mark class="entity" style="background: #CEEEFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells of elderly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">114</span>
</mark>
 individuals was closely associated with impairments in the activation of both AP-1 and NF-AT. By contrast, 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 from elderly subjects with normal levels of IL-2 production exhibited normal activation of AP-1 and NF-AT. In addition, the results of competition experiments analyzing the normal components of NF-AT showed that the age-related reductions in stimulus-dependent NF-AT complexes corresponded to the slow migrating complexes that were composed of c-Fos / c-Jun AP-1. The resting and stimulated levels of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 were reduced in 
<mark class="entity" style="background: #CEEEFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells from certain elderly
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">114</span>
</mark>
 individuals; however, alterations of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 did not correlate with changes in IL-2 expression. Thus, these results show that age-related impairments in the activation of AP-1 and NF-AT are closely associated with decreased expression of IL-2 and further suggest that aberrancies in the signaling pathways important for the induction of transcriptionally active c-Fos / c-Jun AP-1 may contribute to the impaired 
<mark class="entity" style="background: #BADD9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of NF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">28</span>
</mark>
-AT. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96239534">96239534</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 of RNA polymerase III-dependent genes by the 
<mark class="entity" style="background: #EACBAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human T-cell leukemia virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">126</span>
</mark>
 type 1 tax protein. The 
<mark class="entity" style="background: #EACBAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human T-cell leukemia virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">126</span>
</mark>
-encoded tax protein is a potent activator of many viral and cellular genes transcribed by RNA polymerase II. We find that both chromatin and cell extracts derived from 
<mark class="entity" style="background: #EACBAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human T-cell leukemia virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">126</span>
</mark>
 type 1-infected human 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 support higher levels of 5S rRNA and tRNA 
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
 than chromatin or extracts from uninfected 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. The viral protein Tax was likely responsible for this higher level of class II 
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
, as purified Tax was found to stimulate both genes when added to the uninfected cell extract or in reconstituted systems. Both limiting-component transcription assays and 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 assays identified the class III 
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
 factor TFIIIB as the principle target of Tax activity. Surprisingly, we find that Tax increases the effective concentration of active TFIIIB molecules. These data suggest that Tax stimulates RNA polymerase III-dependent 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 by accelerating the rate and / or extent of transcription initiation complex assembly. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96279111">96279111</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Multiple 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 are required for activation of human interleukin 9 gene in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. The genetic elements and regulatory mechanisms responsible for human interleukin 9 ( IL-9 ) 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in a 
<mark class="entity" style="background: #EACBAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human T cell leukemia virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">126</span>
</mark>
 type I-transformed human 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
, C5MJ2, were investigated. We demonstrated that IL-9 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 is controlled, at least in part, by 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
. 
<mark class="entity" style="background: #EA9DCC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transient expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">224</span>
</mark>
 of the luciferase reporter gene linked to serially deleted sequences of the 5'-flanking region of the IL-9 gene has revealed several positive and negative 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 involved in the basal and 
<mark class="entity" style="background: #C99BDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inducible expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">220</span>
</mark>
 of the IL-9 gene in C5MJ2 cells. An AP-1 site at -146 to -140 was shown to be involved in the expression of the IL-9 gene. A proximal region between -46 and -80 was identified as the minimum sequence for the basal and 
<mark class="entity" style="background: #C99BDD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inducible expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">220</span>
</mark>
 of the IL-9 gene in C5MJ2 cells. Within this region, an 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 site at -59 to -50 and its adjacent 20-base pair upstream sequence were demonstrated to play a critical role for the IL-9 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
. DNA-protein binding studies indicated that 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
, c-Jun, and potentially novel proteins ( around 35 kDa ) can bind to this important sequence. Mutations at different sites within this proximal promoter region abolished the 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
 as well as the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
. Taken together, these results suggest that the cooperation of different 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 is essential for IL-9 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96303658">96303658</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Gene transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
 through activation of G-protein-coupled chemoattractant receptors. Receptors for leukocyte chemoattractants, including chemokines, are traditionally considered to be responsible for the activation of special leukocyte functions such as chemotaxis, degranulation, and the release of superoxide anions. Recently, these G-protein-coupled serpentine receptors have been found to transduce signals leading to 
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
 and translation in leukocytes. 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
, such as 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 and AP-1, are activated upon stimulation of the cells with several chemoattractants at physiologically relevant concentrations. 
<mark class="entity" style="background: #ACFEAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Activation of transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">21</span>
</mark>
 through these receptors involves G-protein coupling and the activation of protein kinases. The underlying signaling pathways appear to be different from those utilized by 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
, a better characterized cytokine that induces the transcription of immediate-early genes. Chemoattractants stimulate the expression of several inflammatory cytokines and chemokines, which in turn may activate their respective receptors and initiate an autocrine regulatory mechanism for persistent cytokine and chemokine 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96322726">96322726</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Inhibition of 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 Stat1 activity in mononuclear cell cultures and 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 by the cyclic AMP signaling pathway. 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Activation of T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 results in a cascade of gene activation and subsequent proliferation and differentiation into effector phenotypes. The regulation of 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 belonging to the 
<mark class="entity" style="background: #BCAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    signal transducer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">320</span>
</mark>
 and 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activator of transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 ( STAT ) family was analyzed in PHA-activated mononuclear cells and in purified 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 activated by cross-linking cell surface CD3. Cell activation resulted in a delayed induction of STAT 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity, which was sustained for several days, was composed predominantly of Stat1 and Stat3, and was blocked by cycloheximide and actinomycin D. Increased Stat1 and Stat3 mRNA and protein levels were detected, respectively 4 and 24 h after activation. Stimulation of the cAMP signal transduction pathway, which skews 
<mark class="entity" style="background: #ECEAED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cytokine production
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">183</span>
</mark>
 toward a Th2 pattern, resulted in the preferential suppression of Stat1 activity. cAMP inhibited the induction of expression of IL-2 receptor components, but did not inhibit IL-4 
<mark class="entity" style="background: #BFB9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    receptor alpha-chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">45</span>
</mark>
 and CD69 expression or the induction of 
<mark class="entity" style="background: #EDAF9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activator protein
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">30</span>
</mark>
 1 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
. cAMP signaling inhibited Stat1 at several different levels, including suppression of 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 and down-regulation of Stat1 protein and mRNA levels. Our results demonstrate the regulation of STAT activity by a signaling pathway that regulates the T cell functional phenotype and is distinct from the cytokine-activated Janus kinase-STAT signaling pathway. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96329553">96329553</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #9CFEBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Granulocyte-macrophage colony
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">161</span>
</mark>
-stimulating factor preferentially activates the 94-
<mark class="entity" style="background: #F99BED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kD STAT5A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">286</span>
</mark>
 and an 80-
<mark class="entity" style="background: #F99BED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kD STAT5A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">286</span>
</mark>
 isoform in human 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
. 
<mark class="entity" style="background: #9CFEBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Granulocyte-macrophage colony
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">161</span>
</mark>
-stimulating factor ( 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 ) induces immediate effects in monocytes by activation of the Janus kinase ( JAK2 ) and STAT 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 ( STAT5 ) pathway. Recent studies have identified homologues of STAT5, STAT5A, and STAT5B, as well as lower molecular weight variants of STAT5. To define the activation of the STAT5 homologues and lower molecular weight variant in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 and monocytes differentiated into macrophages by culture in macrophage-CSF ( M-CSF ) , we measured the 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 induced 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of STAT5A, STAT5B, and any lower molecular weight STAT5 isoforms. Freshly isolated monocytes expressed 94-
<mark class="entity" style="background: #F99BED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kD STAT5A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">286</span>
</mark>
, 92-kD STAT5B, and an 80-
<mark class="entity" style="background: #F99BED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kD STAT5A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">286</span>
</mark>
 molecule. Whereas 94-
<mark class="entity" style="background: #F99BED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kD STAT5A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">286</span>
</mark>
 was clearly tyrosine phosphorylated and bound to the enhancer element, the gamma response region ( GRR ) , of the Fc gamma RI gene, substantially less tyrosine phosphorylated STAT5B bound to the immobilized GRR element. Macrophages lost their ability to express the 80-
<mark class="entity" style="background: #F99BED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kD STAT5A
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">286</span>
</mark>
 protein, but retained their ability to activate STAT5A. STAT5A-STAT5A homodimers and STAT5A-STAT5B heterodimers formed in response to 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
. Therefore, activation of STAT5A predominates compared to STAT5B when assayed by direct immunoprecipitation and by evaluation of bound STATs to immobilized GRR. Selective activation of STAT5 homologues in addition to generation of lower molecular isoforms may provide specificity and control to genes expressed in response to cytokines such as 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96338163">96338163</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 recognition of an altered peptide associated with asparagine bond rearrangement. Implications for immunity and vaccine design. The extent to which peptides containing chemically and post-translationally modified amino acid side chains are recognized by primed 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 has not been clearly defined. We report on the 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 recognition of a MHC class I-restricted peptide containing a cyclized asparagine ( succinimide ) residue. This modification of the asparagine side chain is a common intermediate structure during deamidation, isomerization, and bond rearrangements of amide-containing amino acids and also occurs as a side reaction in peptide synthesis. The 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 specifically recognized the succinimide-containing peptide showing only weak cross-reactivity at high concentrations of the parent peptide containing unmodified asparagine. Similarly, 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 raised against the parent peptide did not recognize the succinimide derivative of this peptide. Naturally processed forms of these structures are likely to occur given the importance and frequency of deamidation both in vitro and in vivo. Moreover, since succinimide intermediates of deamidated peptides can occasionally be very stable, these peptides have the potential to act as altered self-Ags with significant implications for autoimmunity. In addition, unwanted and potentially hazardous specificities may be elicited when using synthetic peptides in subunit vaccines in which succinimide residues may form spontaneously during storage or chemical synthesis. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96388957">96388957</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Retinoid differentiation therapy in promyelocytic leukemia. Acute promyelocytic leukemia ( APL ) is a specific type of acute myeloid leukemia characterized by the morphology of the blast cells, a specific t ( 15;17 ) translocation, and risks of definite coagulopathy. Recently this leukemia was further characterized by an exquisite sensitivity to all-
<mark class="entity" style="background: #CC9B9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trans retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">13</span>
</mark>
's differentiation effect and the production of a fusion gene altering the gene of RARalpha and a novel gene PML. In vivo differentiation therapy with retinoids in APL patients follows strict guidelines related both to the APL cell and the biodisposal of all-
<mark class="entity" style="background: #CC9B9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trans retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">13</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D96437028">96437028</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">E3, a hematopoietic-specific transcript directly regulated by the 
<mark class="entity" style="background: #9CDCC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid receptor alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">7</span>
</mark>
. 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 ( 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 ) -induced maturation mediated by the 
<mark class="entity" style="background: #9CDCC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid receptor alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">7</span>
</mark>
 ( 
<mark class="entity" style="background: #9CDCC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">7</span>
</mark>
 ) has been implicated in myeloid development. We have used differential hybridization analysis of a cDNA library constructed from the murine 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
-inducible MPRO promyelocyte 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 to identify immediate-early genes induced by 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 during granulocytic differentiation. E3, one of nine sequences identified, was upregulated in an immediate-early manner, with transcript levels peaking after 60 minutes exposure to 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
. E3 transcripts were 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
-inducible in 
<mark class="entity" style="background: #A9DE9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HL60 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">125</span>
</mark>
, but not in an 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
-resistant subclone, HL60R, that harbors a mutated 
<mark class="entity" style="background: #9CDCC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">7</span>
</mark>
 gene. However, when HL60R cells were transduced with a functional copy of the 
<mark class="entity" style="background: #9CDCC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">7</span>
</mark>
 gene, 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 induced a 10-fold increase in E3 mRNA levels. E3 transcripts are present in the myeloid, B-lymphoid, and erythroid lineages, absent in nonhematopoietic cells, and encode a highly hydrophobic, potentially phosphorylated polypeptide of unknown function with significant homology to a putative protein expressed in myeloid cells. The murine E3 promoter harbors a single bipartite 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 response element which in transient transfection assays conferred 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 sensitivity. These results indicate that E3 is a hematopoietic-specific gene that is an immediate target for the activated 
<mark class="entity" style="background: #9CDCC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">7</span>
</mark>
 during myelopoiesis. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97025698">97025698</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Stimulation of human lymphocyte proliferation and CD40 antigen expression by phosphorothioate oligonucleotides complementary to hepatitis B virus genome. We have studied the proliferation and CD40 antigen expression of lymphocytes, and the cytotoxicity to monocytes, of antisense phosphorothioate oligodeoxynucleotides complementary to the SP II promoter of HBV mRNA ( sequence I ) and the X gene ( sequence II ) in patients with chronic hepatitis B. The oligo sequence I stimulated proliferation of both T and, to a lesser extent, 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
. The percentage of cells expressing CD40 in T and B cell co-cultures increased from 4.2% to 13.8% after oligo stimulation in patients, while it increased form 4.7% to 48.6% in healthy controls. The sense sequence ( sequence III ) of the X gene also enhanced the expression of CD40 antigen in patients with hepatitis B. The proportion of CD40 cells ( 26% ) in a resting B-cell preparation from hepatitis B patients decreased to zero after a 5-day culture with sequence I, but IgG levels in the culture supernatant increased. The cytotoxic properties of monocytes were not influenced by the oligos. These findings indicate that antisense oligos against hepatitis B virus ( HBV ) have mitogenic effects on the proliferation of human lymphocytes in a non-specific manner and may activate 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 to express CD40 antigen. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97028169">97028169</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Dual action of 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 on human embryonic / fetal hematopoiesis: blockade of primitive progenitor proliferation and shift from multipotent / erythroid / monocytic to granulocytic differentiation program. In preliminary studies, we have analyzed the hematopoietic growth factor ( HGF ) requirement of hematopoietic progenitor cells ( HPCs ) purified from embryonic-fetal liver ( FL ) and grown in fetal calf serum-supplemented ( FCS+ ) clonogenic culture. The key role of erythropoietin ( Epo ) for colony formation by early erythroid progenitors ( burst-forming units-erythroid [BFU-E] ) has been confirmed. Furthermore, in the absence of exogenous HGFs, FL monocytic progenitors ( colony-forming unit monocyte [CFU-M] ) generate large colonies exclusively composed of monocytes-macrophages; these colonies are absent in FCS- clonogenic culture. On this basis, we have investigated the role of all-
<mark class="entity" style="background: #CC9B9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trans retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">13</span>
</mark>
 ( ATRA ) and its isomer 9-cis 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 in FL hematopoiesis. Both compounds modulate the growth of purified FL HPCs, which show a dose-dependent shift from mixed / erythroid / monocytic to granulocytic colony formation. Studies on unicellular and paired daughter cell culture unequivocally indicate that the shift is mediated by modulation of the HPC differentiation program to the granulopoietic pathway ( rather than 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
-induced down-modulation of multipotent /erythroid / monocytic HPC growth coupled with recruitment of granulocytic HPCs ) . ATRA and 9-cis 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 also exert their effect on the proliferation of primitive HPCs ( high-proliferative potential colony-forming cells [HPP-CFCs] ) and putative hematopoietic stem cells ( HSCs; assayed in Dexter-type long-term culture ) . High concentrations of either compound ( 1 ) drastically reduced the number of primary HPP-CFC colonies and totally abolished their recloning capacity and ( 2 ) inhibited HSC proliferation. It is crucial that these results mirror recent observations indicating that murine adult HPCs transduced with dominant negative ATRA receptor ( 
<mark class="entity" style="background: #EACEFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">11</span>
</mark>
 ) gene are immortalized and show a selective blockade of granulocytic differentiation. Altogether, these results suggest that ATRA / 9-cis 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 may play a key role in FL hematopoiesis via a dual effect hypothetically mediated by interaction with the 
<mark class="entity" style="background: #EACEFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">11</span>
</mark>
 / 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 heterodimer, ie, inhibition of HSC/ primitive HPC proliferation and induction of CFU-GEMM/ BFU-E / CFU-M shift from the multipotent / erythroid / monocytic to the granulocytic-neutrophilic differentiation program. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97054651">97054651</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #E9ACFA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">291</span>
</mark>
 and cAMP-dependent protein kinase activities in CD40-activated human B lymphocytes. In vitro, human B lymphocytes undergo long-term proliferation when activated through CD40, a protein expressed on their cell surface. The nature of CD40-dependent signals in proliferating fresh human 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epstein-Barr virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
-negative B lymphocytes is currently unknown. In this study, a CD40-dependent B cell culture system was used to examine the role of different signal transduction elements. 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Protein kinase C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 ( 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 ) depletion generated by a long-term phorbol 12 myristate 13-acetate treatment had weak effects on proliferation. Rather, 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 was shown to be directly involved in mediating CD40-dependent signals. The use of the 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 ( 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 ) -specific inhibitor herbimycin A dramatically decreased 
<mark class="entity" style="background: #9FCCAB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cellular proliferation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">150</span>
</mark>
 without altering the activity of the human immunodeficiency virus-1 long terminal repeat ( HIV-1 LTR ) , a promoter largely dependent on the binding of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF- kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) . In contrast, the cAMP-dependent protein kinase specific inhibitor H-89 totally inhibited HIV-1 LTR activity at a concentration as low as 100 nM without affecting 
<mark class="entity" style="background: #9FCCAB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cellular proliferation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">150</span>
</mark>
. 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Electrophoretic mobility shift assay
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ( 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EMSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ) and supershift assay using an 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 binding sequence from the kappa light chain as a probe, revealed that both p65 ( RelA ) and c-Rel were present in CD40-stimulated 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
. While 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 depletion did not alter the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 level, treatment of B lymphocytes with H-89 or herbimycin A provoked a decrease in the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 level. These observations establish the importance of different signal transducing pathways leading to CD40 activation of B lymphocytes. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97064186">97064186</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Lack of IL-12 signaling in human allergen-specific Th2 cells. IL-12 is a powerful skewer of CD4+ T cell responses toward the Th1 phenotype by inducing 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 production in naive Th cells. In the present study we addressed the question of whether IL-12 can reverse established Th2 responses into Th1 / Th0 responses by inducing 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 production in memory Th2 cells. To this aim, allergen-specific CD4+ T cell clones ( TCC ) were generated from the 
<mark class="entity" style="background: #BBEFAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">97</span>
</mark>
 of three atopic patients, and their cytokine profiles were analyzed. The majority of these TCC exhibited a strongly polarized Th2 cytokine profile, and the production of 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 could not be induced by exogenous IL-12. Only those TCC with low 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 levels in the absence of IL-12 responded to IL-12 by additional enhancement of 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
 production. The IL-12 nonresponsiveness of the Th2 clones was further evident by the total lack of IL-12-induced phosphorylation of STAT4 ( 
<mark class="entity" style="background: #BCAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    signal transducer
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">320</span>
</mark>
 and activator of transcription-4 ) , a 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 that is typically involved in IL-12 signaling. Consequently, IL-12 also failed to induce the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity of STAT4-containing complexes in the nuclei of these Th2 clones. All TCC expressed equal levels of the low-affinity IL-12R beta1 subunit. Our results indicate that human allergen-specific Th cells with strongly polarized Th2 cytokine profiles do not respond to IL-12 and, therefore, cannot be induced to produce 
<mark class="entity" style="background: #AFBCDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">244</span>
</mark>
. The apparent high frequency of IL-12-nonresponsive Th cells within the allergen-specific populations in atopic patients predicts a limited skewing potential of IL-12 in the case of established Th2 responses, but only affecting newly recruited naive Th cells. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97162234">97162234</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 activation in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 stimulated with lipopolysaccharide is inhibited by fibroblast conditioned medium and exogenous PGE2. The 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) is thought to be crucially involved in the gene activation of several cytokines, including 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ( 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ) . Previously, we showed that fibroblast conditioned medium ( FCM ) is able to inhibit both 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 mRNA accumulation and protein release in 
<mark class="entity" style="background: #BBEFAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">97</span>
</mark>
-derived 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 ( PBM ) stimulated with lipopolysaccharide ( LPS ) . In this study we have investigated the effect of FCM on the LPS-induced 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activity of NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
, by means of electrophoretic shift assay ( 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EMSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ) . We provide evidence that FCM strongly inhibits the LPS-induced 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 in PBM. Furthermore, we show that exogenous PGE2 mimics the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 inhibitory effect of FCM. On the other hand, FCM produced in the presence of indomethacin does not inhibit 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 by LPS. Our results lend further support to the hypothesis that inflammatory and immune responses of monocytes / macrophages may be modulated at the molecular level by signals originating from tissue structural cells such as fibroblasts. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97207294">97207294</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Interleukin-4 signaling in B lymphocytes from patients with X-linked severe combined immunodeficiency. Interleukin-4 ( IL-4 ) is an important cytokine for B and 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocyte
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 function and mediates its effects via a receptor that contains gammac. 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 derived from patients with X-linked severe combined immunodeficiency ( X-SCID ) are deficient in gammac and provide a useful model in which to dissect the role of this subunit in IL-4-mediated signaling. We found that although IL-4 stimulation of X-SCID 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 did not result in Janus tyrosine kinase-3 ( JAK3 ) phosphorylation, other IL-4 substrates including JAK1 and IRS-1 were phosphorylated. Additionally, we detected 
<mark class="entity" style="background: #BCAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    signal transducers
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">320</span>
</mark>
 and 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activators of transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 6 ( STAT6 ) 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 and 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity in X-SCID 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 with a wide range of gammac mutations. However, reconstitution of these X-SCID 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 with gammac enhanced IL-4-mediated responses including STAT6 phosphorylation and 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity and resulted in increased CD23 expression. Thus, gammac is not necessary to trigger IL-4-mediated responses in 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
, but its presence is important for optimal IL-4-signaling. These results suggest that two distinct IL-4 signaling pathways exist. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97211823">97211823</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Nuclear Rel-A and c-Rel protein complexes are differentially distributed within human thymocytes. 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) /Rel proteins are inducible transcriptional regulators of numerous cellular genes. They are particularly abundant in lymphoid tissues and are thought to be critical for the 
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription of genes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
 involved in immune and 
<mark class="entity" style="background: #FEFFFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inflammatory responses
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">282</span>
</mark>
. We have reported previously that a 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear NF-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 was present in freshly extracted human thymocytes in the absence of in vitro treatment of these cells. In the present report, we identified 
<mark class="entity" style="background: #BCFEDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">76</span>
</mark>
 extracted from human thymocyte nuclei as being p50 / p65 and p50 / c-Rel complexes. Immunochemical and immunofluorescent staining of thymus sections using specific Abs allowed visualization of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 proteins in both thymocytes and nonthymocyte cells. This detection suggested a preferential activation of p50 / c-Rel in medullary thymocytes, whereas p50 / p65 was present in both cortical and medullary regions of human thymus lobules. However, the intensity of p65 labeling was much higher in several thymocytes from the medulla. p65, p50, and c-Rel activities were found in both CD4- and CD8-positive thymocytes. These observations suggest that p65 and c-Rel complexes play distinct roles in 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 and that both forms of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 play critical roles during late stages of the intrathymic maturation of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97263762">97263762</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Involvement of an SAF-like 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 in the activation of serum amyloid A gene in monocyte / 
<mark class="entity" style="background: #9CDEFC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    macrophage cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">134</span>
</mark>
 by lipopolysaccharide. Serum amyloid A ( SAA ) has been linked to atherosclerosis because of its ability to remodel high-density lipoprotein by the depletion of apolipoprotein A1, its ability to bind cholesterol, and its presence in the atherosclerotic plaques of coronary and carotid arteries. In the present study, we investigated the induction mechanism of SAA gene in THP-1 monocyte / 
<mark class="entity" style="background: #9CDEFC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    macrophage cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">134</span>
</mark>
 which play a critical role in the development of atherosclerotic fatty streak and plaque formation. We and others have shown that SAA gene is induced in monocyte / 
<mark class="entity" style="background: #9CDEFC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    macrophage cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">134</span>
</mark>
 by lipopolysaccharide ( LPS ) . By promoter function analysis, we show that the SAA promoter sequence between -280 and -226 can confer LPS responsiveness. Gel 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assay
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 detected an induced 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity in these cells in response to LPS. Characterization of the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 protein by UV cross-linking, Southwestern blot, and antibody ablation / supershift assays revealed that it is similar to a recently reported 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 designated SAF. These results demonstrated that LPS-mediated SAA gene induction in monocyte / 
<mark class="entity" style="background: #9CDEFC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    macrophage cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">134</span>
</mark>
 is primarily due to the induction of SAF activity. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97303223">97303223</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Homodimerization of the human interleukin 4 
<mark class="entity" style="background: #BFB9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    receptor alpha chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">45</span>
</mark>
 induces Cepsilon germline transcripts in 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 in the absence of the interleukin 2 receptor gamma chain. The cytokines interleukin ( IL ) -4 and IL-13 play a critical role in inducing Cepsilon germline transcripts and IgE isotype switching in human 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
. The IL-4 receptor ( IL-4R ) in 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 is composed of two chains, the IL-4-binding 
<mark class="entity" style="background: #BB9DCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IL-4Ralpha chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">155</span>
</mark>
, which is shared with the IL-13R, and the IL-2Rgamma ( gammac ) chain, which is shared with IL-7R, IL-9R, and IL-15R. IL-4 induces Cepsilon germline transcripts and IgE isotype switching in 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 from patients with gammac chain deficiency. Induction of Cepsilon germline transcripts by IL-4 in 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 that lack the gammac chain may involve signaling via the IL-13R. Alternatively, the 
<mark class="entity" style="background: #BB9DCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IL-4Ralpha chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">155</span>
</mark>
 may transduce intracellular signals that lead to Cepsilon 
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
 independently of its association with other chains. We show that ligand-induced homodimerization of chimeric surface receptors consisting of the extracellular and transmembrane domains of the erythropoietin receptor and of the intracellular domain of IL-4Ralpha induces Janus kinase 1 ( Jak1 ) activation, STAT6 activation, and Cepsilon germline transcripts in human B 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 BJAB. Disruption of the Jak1-binding proline-rich Box1 region of IL-4Ralpha abolished signaling by this chimeric receptor. Furthermore, 
<mark class="entity" style="background: #DAC9AC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    B cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">70</span>
</mark>
 transfected with a chimeric CD8alpha / IL-4Ralpha receptor, which is expressed on the cell surface as a homodimer, constitutively expressed Cepsilon germline transcripts. These results suggest that homodimerization of the 
<mark class="entity" style="background: #BB9DCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IL-4Ralpha chain
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">155</span>
</mark>
 is sufficient to transduce Jak1-dependent intracellular signals that lead to IgE isotype switching. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97307577">97307577</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Abnormal 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocyte
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 development induced by targeted overexpression of Ikappa B alpha. A role in thymic maturation for factors of the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 family has long been suspected, but not yet proven. Transgenic mice with a lymphocyte-specific defect in 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 were produced by targeted expression of human Ikappa B alpha. The thymic cellularity of these mice was significantly decreased. The proportion of mature, TCRhigh thymocytes of the alphabeta lineage was reduced, and the remaining TCRhigh population contained an unusually high proportion of double-positive cells. This defect in maturation resulted in a transgene dose-dependent reduction in peripheral 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
, with the CD8 lineage being more severely affected. These data provide direct evidence for the involvement of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 / Rel family proteins in late stages of 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocyte
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 development, coincident with positive and negative selection. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97324097">97324097</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transcriptional activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 and constitutive nuclear localization of the ETS protein Elf-1. Elf-1 is a lymphoid-specific 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 that belongs to the ETS protein family. It can 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bind to DNA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 target sequences within a variety of cytokine genes. We demonstrate that Elf-1 is constitutively localized in the nucleus which is dependent on the presence of amino acids 86-265. Analysis of Gal4-Elf-1 fusion proteins revealed that the N-terminal 86 amino acids of Elf-1 contain a 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 domain, the activity of which is attenuated by an internal repression domain. Furthermore, Elf-1 interacts specifically with the E74 target sequence and can stimulate transcription driven by the E74 site independent of mitogenic signaling. Thus, Elf-1 is able to stimulate 
<mark class="entity" style="background: #9EAFCB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene transcription
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">250</span>
</mark>
 which may be required for the development and activity of lymphocytes. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97376857">97376857</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Involvement of Rel, Fos, and Jun proteins in binding activity to the IL-2 promoter 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28 response element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 / AP-1 sequence in human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. CD28 is an important costimulatory molecule in the activation of human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Costimulation of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 through both the Ag receptor and CD28 leads to high level IL-2 production, which is vital to the development of an immune response in vivo. Previous reports have suggested the CD28 stimulation contributes to the activation of the IL-2 promoter by up-regulating the activity of several 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
, including AP-1 and 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) /Rel family members as well as an uncharacterized 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 called CD28 response complex. While several lines of investigation have suggested that 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 / 
<mark class="entity" style="background: #CEEBDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rel family members
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">238</span>
</mark>
 make up the CD28 response complex 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
, other work has not supported this conclusion. Recent studies suggest that the 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28 response element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 ( 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28RE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 ) does not function independently but works instead in conjunction with the adjacent promoter proximal AP-1-binding site and this hypothesis is confirmed here. Also in the current study, binding activity to the 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28RE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 / AP-1 sequence of the IL-2 promoter is evaluated. Although four specific complexes can be detected binding to this sequence, only one of these complexes is specific for both the 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28RE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 and the adjacent AP-1 site. Of the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 / 
<mark class="entity" style="background: #CEEBDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rel family members
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">238</span>
</mark>
 tested, this 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28RE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 / AP-1-specific complex contains predominantly c-Rel, despite the fact that both p50 and RelA can efficiently bind to the 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28RE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
. c-Fos and c-Jun are also found in this 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28RE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 / AP-1-specific complex. These data indicate that functional complexes encompassing both the 
<mark class="entity" style="background: #C9EF9F; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CD28RE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">107</span>
</mark>
 and the AP-1-binding sites influence IL-2 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
 in CD28-costimulated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97436422">97436422</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Transcriptional regulation during myelopoiesis. The coordinated production of all blood cells from a common stem cell is a highly regulated process involving successive stages of commitment and differentiation. From analyses of mice deficient in 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 genes and from the characterizations of chromosome breakpoints in human leukemias, it has become evident that 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 are important regulators of hematopoiesis. During myelopoiesis, which includes the development of granulocytic and monocytic lineages, 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 from several families are active, including AML1 / CBF beta, C / EBP, Ets, c-Myb, HOX, and MZF-1. Few of these factors are expressed exclusively in myeloid cells; instead it appears that they cooperatively regulate transcription of myeloid-specific genes. Here we discuss recent advances in transcriptional regulation during myelopoiesis. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97445683">97445683</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Rel / 
<mark class="entity" style="background: #AEBAAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">77</span>
</mark>
 and the control of apoptosis. The process of apoptosis is used to eliminate unwanted cells from a wide variety of organisms. Various extracellular signals, often converging in common intracellular pathways, can induce apoptosis in a cell-type-specific fashion. Recent work from several laboratories has demonstrated that Rel / 
<mark class="entity" style="background: #AEBAAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">77</span>
</mark>
 regulate apoptosis in many cell types. In most cells, Rel / 
<mark class="entity" style="background: #AEBAAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">77</span>
</mark>
 appear to mediate survival signals that protect cells from apoptosis; however, under some circumstances, activation of these factors may also promote apoptosis. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97456880">97456880</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Four 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P-like elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 are required for optimal transcription of the mouse IL-4 gene: involvement of a distinct set of 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 and activator protein-1 family proteins. We previously identified the P sequence as a critical 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 of the human IL-4 promoter. In the mouse IL-4 promoter, there are five elements homologous to the human P sequence designated conserved lymphokine element 0 ( CLE0 ) , P, P2, P3 and P4. To characterize the role of these 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P-like elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 and their binding factors in the native promoter, we did transient transfection and 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assays
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ( 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EMSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ) . Transfection of EL-4 cells with the IL-4 promoter-reporter constructs carrying mutated 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P-like elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 showed that four 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P-like elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
, CLE0, P, P2 and P4, but not P3, were required for optimal activation of the IL-4 promoter. 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EMSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 showed that both constitutive and inducible complexes bound to CLE0, P, P2 and P4, whereas only a constitutive complex bound to P3. In competition and antibody supershift assays in 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EMSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
, complexes formed with P or P2 proved to contain 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 ( NFAT ) family proteins as major components. 
<mark class="entity" style="background: #EDAF9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Activator protein
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">30</span>
</mark>
 ( 
<mark class="entity" style="background: #EDAF9B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">30</span>
</mark>
 ) -1 family proteins interacted with CLE0, P, P2 and P4. NFAT / AP-1 complex formed only with P and P2. Cross-competition assays among the 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P-like elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 revealed element-specific and common complexes. Six tandem repeats of the 
<mark class="entity" style="background: #CFAFDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    P element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">209</span>
</mark>
 linked to the SV40 promoter responded to phorbol 12-myristate 13-acetate, while that of other elements did not. It would thus appear that components of each P-like element-binding complexes are not identical and may coordinately contribute to 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97458245">97458245</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #BADD9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-AT activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">28</span>
</mark>
 induced by a CAML-interacting member of the 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 receptor superfamily. Activation of the 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 ( NF-AT ) is a key event underlying lymphocyte action. The CAML ( calcium-modulator and cyclophilin ligand ) protein is a coinducer of 
<mark class="entity" style="background: #BADD9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-AT activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">28</span>
</mark>
 when overexpressed in Jurkat 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. A member of the 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 receptor superfamily was isolated by virtue of its affinity for CAML. Cross-linking of this lymphocyte-specific protein, designated TACI ( transmembrane activator and CAML-interactor ) , on the surface of transfected 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
 with TACI-specific antibodies led to activation of the 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 NF-AT, AP-1, and NFkappa B. TACI-induced 
<mark class="entity" style="background: #BADD9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of NF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">28</span>
</mark>
-AT was specifically blocked by a dominant-negative CAML mutant, thus implicating CAML as a signaling intermediate. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D97468093">97468093</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Phospholipase C gamma 1 overexpression and activation induced by interferon beta in human 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
: an ISGF3-independent response. Interferons exert their antiviral, antiproliferative and immunoregulatory activities by stimulating the expression of several genes. Such genes disclose a common element within their promoters, defined Interferon Stimulated Response Element ( ISRE ) , which binds a 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 ( s ) translocated from the cytoplasm to the nucleus ( ISGF3 ) after the binding of interferon ( IFN ) to the specific receptor. Here we report the induction of the synthesis and of the hydrolytic activity of phospholipase C gamma 1 ( 
<mark class="entity" style="background: #DABDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLC gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">245</span>
</mark>
 1 ) in human 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 by IFN-beta. The increased level of 
<mark class="entity" style="background: #DABDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLC gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">245</span>
</mark>
 1 becomes evident after 90 min of IFN-beta treatment and is still detectable after 24 h. Neither the 
<mark class="entity" style="background: #DABDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLC gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">245</span>
</mark>
 1 overexpression induced by IFN nor the increased hydrolytic activity of the enzyme appear to be affected by pretreatment of the cells with the 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 inhibitor genistein, which is known to prevent the association of ISGF3 components. These results suggest that in human 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 IFN-beta can activate other 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 ( s ) distinct from ISGF3 to regulate 
<mark class="entity" style="background: #DABDFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PLC gamma
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">245</span>
</mark>
 1 expression. In addition, the ability of this enzyme to hydrolyse PIP2, also in the presence of genistein, implies the possibility that this enzyme can exert its hydrolytic activity independently of 
<mark class="entity" style="background: #CDADB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinase activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">25</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98001571">98001571</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Blockade of 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 by dithiocarbamates involves novel mechanisms of inhibition of 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Dithiocarbamates ( DTCs ) have recently been reported as powerful inhibitors of 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 in a number of cell types. Given the role of this 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 in the regulation of 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in the 
<mark class="entity" style="background: #FEFFFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inflammatory response
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">282</span>
</mark>
, 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 inhibitors have been suggested as potential therapeutic drugs for inflammatory diseases. We show here that DTCs inhibited both interleukin 2 ( IL-2 ) synthesis and membrane expression of antigens which are induced during 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
. This inhibition, which occurred with a parallel activation of c-Jun transactivating functions and expression, was reflected by transfection experiments at the IL-2 promoter level, and involved not only the inhibition of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
-driven reporter activation but also that of 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 ( NFAT ) . Accordingly, 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assays
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ( 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EMSAs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ) indicated that 
<mark class="entity" style="background: #CFCBBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    pyrrolidine DTC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">202</span>
</mark>
 ( 
<mark class="entity" style="background: #CFCBBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PDTC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">202</span>
</mark>
 ) prevented 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
, and NFAT 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activity in T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 stimulated with either 
<mark class="entity" style="background: #EF9DBE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phorbol myristate acetate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">4</span>
</mark>
 plus ionophore or antibodies against the CD3-
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 complex and simultaneously activated the binding of AP-1. Furthermore, 
<mark class="entity" style="background: #CFCBBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PDTC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">202</span>
</mark>
 differentially targeted both NFATp and NFATc family members, inhibiting the transactivation functions of NFATp and mRNA induction of NFATc. Strikingly, Western blotting and immunocytochemical experiments indicated that 
<mark class="entity" style="background: #CFCBBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PDTC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">202</span>
</mark>
 promoted a transient and rapid shuttling of NFATp and NFATc, leading to their accelerated export from the nucleus of activated 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. We propose that the activation of an NFAT kinase by 
<mark class="entity" style="background: #CFCBBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PDTC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">202</span>
</mark>
 could be responsible for the rapid shuttling of the NFAT, therefore transiently converting the sustained transactivation of this 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 that occurs during lymphocyte activation, and show that c-Jun NH2-terminal kinase ( JNK ) can act by directly phosphorylating NFATp. In addition, the combined inhibitory effects on NFAT and NF-KB support a potential use of DTCs as immunosuppressants. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98012705">98012705</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Dysregulation of monocytic 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 by oxidized low-density lipoprotein. 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) /Rel 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 may be involved in atherosclerosis, as is suggested by the presence of activated 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 in human atherosclerotic lesions. The aim of the present study was to investigate the effects of oxidized LDL ( oxLDL ) on the 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 system in human THP-1 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
 as well as adherent monocytes. Our results demonstrate that short-term incubation of these cells with oxLDL activated p50 / p65 containing 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 dimers and induced the expression of the target gene IL-8. This 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 was inhibited by the antioxidant and H2O2 scavenger pyrrolidine dithiocarbamate and the proteasome inhibitor PSI. The oxLDL-induced 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 was accompanied by an initial depletion of I kappa B-alpha followed by a slight transient increase in the level of this inhibitor protein. In contrast, long-term treatment with oxLDL prevented the lipopolysaccharide-induced depletion of I kappa B-alpha, accompanied by an inhibition of both 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and the expression of 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 and interleukin-1 beta genes. These observations provide additional evidence that oxLDL is a potent modulator of 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 and suggest that ( dys ) regulation of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 / Rel is likely to play an important role in atherogenesis. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98038749">98038749</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Regulation of Id3 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
 function by Cdk-2-
<mark class="entity" style="background: #FA9BBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">191</span>
</mark>
. The functions of basic helix-loop-helix ( bHLH ) 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 in activating differentiation-linked 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 and in inducing G1 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
 arrest are negatively regulated by members of the Id family of HLH proteins. These bHLH antagonists are induced during a mitogenic signalling response, and they function by sequestering their bHLH targets in inactive heterodimers that are unable to bind to specific gene regulatory ( E box ) sequences. Recently, cyclin E-Cdk2- and cyclin A-Cdk2-
<mark class="entity" style="background: #FA9BBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">191</span>
</mark>
 of a single conserved serine residue ( Ser5 ) in Id2 has been shown to occur during late G1-to-S phase transition of the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
, and this neutralizes the function of Id2 in abrogating E-box-dependent bHLH homo -or heterodimer complex formation in vitro ( E.Hara, M.Hall, and G.Peters, EMBO J.16:332-342, 1997 ) . We now show that an analogous 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell-cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
-regulated phosphorylation of Id3 alters the specificity of Id3 for abrogating both E-box-dependent bHLH homo- or heterodimer complex formation in vitro and E-box-dependent reporter gene function in vivo. Furthermore, compared with wild-type Id3, an Id3 Asp5 mutant ( mimicking phosphorylation ) is unable to promote 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
 S phase entry in transfected fibroblasts, whereas an Id3 Ala5 mutant ( ablating phosphorylation ) displays an activity significantly greater than that of wild-type Id3 protein. Cdk2-
<mark class="entity" style="background: #FA9BBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">191</span>
</mark>
 therefore provides a switch during late G1-to-S phase that both nullifies an early G1 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
 regulatory function of Id3 and modulates its target bHLH specificity. These data also demonstrate that the ability of Id3 to promote 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
 S phase entry is not simply a function of its ability to modulate bHLH heterodimer-dependent 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 and establish a biologically important mechanism through which Cdk2 and Id-bHLH functions are integrated in the coordination of cell proliferation and differentiation. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98089072">98089072</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Estrogen receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 diminishes 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activities of chicken GATA-1 and-binding proteins. The 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    estrogen receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 ( 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 ) repressed erythroid differentiation and 
<mark class="entity" style="background: #BAB9EF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid-specific gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">214</span>
</mark>
. In this study, we investigated the effect of 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 alpha ( referred to throughout as 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 ) on 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 
<mark class="entity" style="background: #ACFEAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activities of transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">21</span>
</mark>
 involved in regulating the 
<mark class="entity" style="background: #BAB9EF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    expression of erythroid-specific genes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">214</span>
</mark>
, and, in particular, the histone H5 gene. Using 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assays
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
, we found that in the presence of rabbit reticulocyte lysate, human 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 reduced the binding activities of chicken immature erythrocyte nuclear extracted proteins toandsites in the H5 promoter and enhancer. In contrast, the binding activities of NF1 and Sp1 were not affected by 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
. Binding of 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 to an estrogen response element was enhanced by addition of rabbit reticulocyte lysate. This lysate was also necessary for 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 to diminish the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activity of GATA-1. These results suggest that additional factor ( s ) are necessary for full 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 function. Both GATA-1 and-binding proteins are critical for the developmentally regulated 
<mark class="entity" style="background: #BAB9EF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    expression of erythroid-specific genes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">214</span>
</mark>
. We hypothesize that interference in 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 activities of GATA-1 and-binding proteins is the mechanism by which the 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ER
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 inhibits regulation of these genes. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98090689">98090689</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Constitutive expression c-fos, c-jun, and 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 mRNA is in nucleated fetal blood cells and up-regulation of c-fos and c-jun with anti-CD3 stimulation. Fetal and neonatal lymphocytes are relatively resistant to activation and 
<mark class="entity" style="background: #ECEAED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cytokine production
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">183</span>
</mark>
 when stimulated either via their T-cell antigen receptors or lectins. The molecular mechanism ( s ) responsible for this phenomenon have not been clearly elucidated. We have hypothesized that such defects in fetal / neonatal 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 may be due to lack of expression of the transcriptional 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory elements
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
 required for 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
. We used reverse transcriptase-
<mark class="entity" style="background: #BFCBCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polymerase chain reaction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">156</span>
</mark>
 to examine both fetal and term neonatal cord bloods for mRNA expression of three 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 implicated in 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
: c-jun, c-fos, and 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( p50 subunit ) . We demonstrate that mRNAs for all three of these regulatory factors are expressed in fetal blood cells by the 27th week of gestation and in term cord bloods. Activation of term infant cord blood mononuclear cells with anti-CD3 monoclonal antibodies resulted in up-regulation of both c-jun and c-fos mRNAs within 15 min of stimulation. However, secretion of IL-2 by anti-CD3-stimulated cord blood mononuclear cells was still blunted compared with control cells from adults. We conclude that fetal nucleated blood cells constitutively express important genes for cytokine regulation and are able to increase intracellular accumulation of the mRNAs for these factors in response to anti-CD3 stimulation. Thus, qualitative differences in the capacity to regulate these factors could not be shown in fetal blood cells. Quantitative experiments comparing binding of these 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 to the IL-2 promoter are currently under investigation. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98104459">98104459</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 / 
<mark class="entity" style="background: #CEEBDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rel family members
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">238</span>
</mark>
 regulating the 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 promoter in monocytic 
<mark class="entity" style="background: #CEFDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    THP-1 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">145</span>
</mark>
. A 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B-site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
 was identified in the promoter of the 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    intercellular adhesion molecule-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 ( 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 ) gene, which is involved in regulation of 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 expression by 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ( 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ) and glucocorticoids. We now report on the 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 which bind and transactivate this enhancer sequence. In vitro, the 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
 appeared to bind RelA and c-Rel homodimers as well as heterodimers with 
<mark class="entity" style="background: #FAFBDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">84</span>
</mark>
, but weakly 
<mark class="entity" style="background: #FAFBDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">84</span>
</mark>
 homodimers. In addition, both RelA and c-Rel, but not 
<mark class="entity" style="background: #FAFBDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">84</span>
</mark>
, were shown to transactivate an 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 kappa B-reporter construct. In monocytic 
<mark class="entity" style="background: #CEFDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    THP-1 cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">145</span>
</mark>
 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 induced two nuclear complexes which in vitro bound to the 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
. Using antibodies in an electrophoretic mobility supershift assay, one of these complexes was shown to contain 
<mark class="entity" style="background: #FAFBDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">84</span>
</mark>
 and RelA, and to bind with higher affinity to the consensus 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
 in the 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 long terminal repeat. The second complex contained RelA, and exhibited higher affinity towards the 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 kappa B than to the 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 
<mark class="entity" style="background: #9AAEE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    kappa B site
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">81</span>
</mark>
. The 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 was shown to repress activity of both the RelA homodimer and the 
<mark class="entity" style="background: #FAFBDE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">84</span>
</mark>
 / RelA heterodimer. We argue that in vivo RelA homodimers are likely to play a dominant role in 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
-induced 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 transcription in 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98104462">98104462</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">LPS tolerance in monocytes / macrophages: three 3' cytosins are required in the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 motif for detection of upregulated 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 p50 homodimers. When monocytes are stimulated with LPS ( lipopolysaccharide ) repeatedly then the initially high expression of the 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ( 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ) gene is only very low, i.e. the cells are tolerant to LPS. 
<mark class="entity" style="background: #FD9DDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tolerant cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">146</span>
</mark>
 still express the CD14 receptor and they can still be activated to mobilize 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 into nucleus. Analysis of the binding proteins employing the -605 motif of the human 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 promoter () revealed that in 
<mark class="entity" style="background: #FD9DDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tolerant cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">146</span>
</mark>
 of the human monocytic 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 Mono Mac 6 there is a predominance of p50p50 of NF-kappa B. We now show that a mutant motif that exchanges the terminal 3' C for a G fails to bind the p50 homodimer that is upregulated in LPS toler ant human Mono Mac 6 cells. The same is true for 
<mark class="entity" style="background: #EFCE99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear extracts
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">226</span>
</mark>
 taken from the murine P388D1 macrophage 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 when tested with the -516 motif of the murine 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 promoter () . Here the wild type motif gives efficient binding of p50p50 that again is upregulated in 
<mark class="entity" style="background: #FD9DDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tolerant cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">146</span>
</mark>
 whereas a mutant with a 3' G shows hardly any binding of p50p50. Conversely, the murine kappa light chain enhancer motif () does not efficiently bind the nuclear p50p50 from tolerant murine P388 macrophages. Binding is, however, readily detected when the 3' G is replaced by a C. These data show that the detection of upregulated p50 homodimers in LPS 
<mark class="entity" style="background: #FD9DDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tolerant cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">146</span>
</mark>
 is dependent on subtle differences in the sequence of the 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 motif. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98133462">98133462</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in cord blood lymphocytes of healthy neonates and of preterms suffering from respiratory distress syndrome. We measured the number of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ( 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ) in cord blood lymphocytes and the binding affinity ( Kd ) in 15 term and in 20 preterm babies. Thirteen preterms of the latter group received prenatal steroid treatment. Seven preterms developed 
<mark class="entity" style="background: #AD9CFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neonatal respiratory distress syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">196</span>
</mark>
 ( 
<mark class="entity" style="background: #AD9CFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NRDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">196</span>
</mark>
 ) . The number of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 and the Kd were similar in the term and preterm ( with and without 
<mark class="entity" style="background: #AD9CFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NRDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">196</span>
</mark>
 ) babies. The maximum ( 3H ) -thymidine incorporation into DNA of cord blood lymphocytes from all preterms, with or without 
<mark class="entity" style="background: #AD9CFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NRDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">196</span>
</mark>
 was suppressed when compared to that from term babies or adults. This could partly be explained by the antenatal steroid treatment. Sensitivity ( ID50 ) of the lymphocytes for the inhibitory effect of dexamethasone was the same in all groups. In this study on the number and function of 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in lymphocytes, we were unable to find a relation between the functionality of the 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 and the development of 
<mark class="entity" style="background: #AD9CFD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NRDS
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">196</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98230439">98230439</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Human immunodeficiency virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 type 1 long terminal repeat quasispecies differ in basal transcription and 
<mark class="entity" style="background: #9ABFAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">232</span>
</mark>
 recruitment in human glial cells and lymphocytes. The generation of genomic diversity during the course of infection has the potential to affect all aspects of HIV-1 replication, including expression of the proviral genome. To gain a better understanding of the impact of long terminal repeat ( LTR ) sequence diversity on LTR-directed 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in cells of the central nervous system ( CNS ) and 
<mark class="entity" style="background: #9AF9D9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    immune system
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">277</span>
</mark>
, we amplified and cloned LTRs from proviral DNA in HIV-1-infected 
<mark class="entity" style="background: #BBEFAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">97</span>
</mark>
. Sequence analysis of nineteen LTRs cloned from 2 adult and 3 pediatric patients revealed an average of 33 nucleotide changes ( with respect to the sequence of the LAI LTR ) within the 455-bp U3 region. 
<mark class="entity" style="background: #EA9DCC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Transient expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">224</span>
</mark>
 analyses in cells of neuroglial and lymphocytic origin demonstrated that some of these LTRs had activities which varied significantly from the LAI LTR in U-373 MG cells ( an astrocytoma 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 ) as well as in 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
 ( a CD4-positive lymphocyte 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 ) . While LTRs which demonstrated the highest activities in U-373 MG cells also yielded high activities in 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
, the LTRs were generally more active in 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
 when compared to the LAI LTR. Differences in LTR sequence also resulted in differences in 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 recruitment to cis-acting sites within the U3 region of the LTR, as demonstrated by 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assays
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
. In particular, naturally occurring sequence variation impacted 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 binding to an 
<mark class="entity" style="background: #ACFEAD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activating transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">21</span>
</mark>
 / cAMP response element binding ( ATF / CREB ) binding site ( located between the LEF-1 and distal 
<mark class="entity" style="background: #AEBAAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">77</span>
</mark>
 binding sites ) that we identified in previous studies of the HIV-1 LTR. These findings suggest that LTR sequence changes can significantly affect basal LTR function and 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 recruitment, which may, in turn, alter the course of viral replication in cells of CNS and 
<mark class="entity" style="background: #9AF9D9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    immune system
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">277</span>
</mark>
 origin. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98380286">98380286</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Stimulation of B and 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 activates expression of transcription and differentiation factors. During B and T cell differentiation and proliferation many genes are induced or repressed while certain genes are constitutively expressed. To investigate processes related to B and 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
, the 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 of stimulated and nonstimulated Ramos and 
<mark class="entity" style="background: #B9BBBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Jurkat cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">129</span>
</mark>
 was studied using cDNA microarray technology. Simultaneous analysis of close to 600 genes indicated highest increase in the expression of certain transcription, differentiation and proliferation factors. Many of these genes have not previously been shown to funcion in the stimulated lymphocytes. Also genes encoding proteins involved in DNA replication, binding, transcription and translation were induced. Large part of the activated genes were under very stringent regulation being expressed only after stimulation. The mechanism and function of the expressed genes during lymphocyte differentiation and in disorders is discussed. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98400423">98400423</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Retinoid X receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 and c-cerbA / thyroid hormone receptor regulate 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 growth and differentiation. Nuclear receptors are important regulators of 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 development. Here we investigated the impact of 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoid X receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 ( 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 ) , 
<mark class="entity" style="background: #EACEFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">11</span>
</mark>
 ( 
<mark class="entity" style="background: #EACEFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">11</span>
</mark>
 ) , and of the c-erbA / thyroid hormone ( T3 ) receptor ( c-erbA / TR ) on growth and differentiation of 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 using an in vitro culture system of stem cell factor-dependent erythroid progenitors. 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
, 
<mark class="entity" style="background: #EACEFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RAR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">11</span>
</mark>
, and c-erbA / TR-specific ligands were found to induce 
<mark class="entity" style="background: #BAB9EF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid-specific gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">214</span>
</mark>
 and to accelerate erythroid differentiation in culture, with T3 being most effective. Furthermore, while ligand-activated c-erbA / TR accelerated differentiation, unliganded c-erbA / TR effectively blocked differentiation and supported sustained progenitor growth in culture. Thus, c-erbA / TR appears to act as a binary switch affecting 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 fate: unliganded c-erbA / TR supports growth while ligand-activated c-erbA / TR induces differentiation. Additionally, to determine the impact of 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 for 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 development, dominant interfering mutant RXRs, lacking the 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activator
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 functions AF-1 and AF-2, or AF-2 only, or the entire 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 domain, were introduced into erythroid progenitor cells via recombinant retrovirus vectors and analyzed for 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
-specific effects. It was found that expression of wild-type 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 and of the 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 mutants devoid of AF-1 and / or AF-2 supported a transient outgrowth of 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
. In marked contrast, expression of the dominant interfering deltaDNA-binding domain 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
, containing a deletion of the entire 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 domain, was incompatible with 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 growth in vitro, suggesting a pivotal role of 
<mark class="entity" style="background: #E9DFBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RXR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">314</span>
</mark>
 for 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 development. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98406200">98406200</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">The 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epstein-Barr virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. The transition of 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epstein-Barr virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 ( 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 ) from latency into the lytic cycle is associated with the expression of two immediate-early viral genes, BZLF1 and BRLF1. Overexpression of ZEBRA, the product of BZLF1, is sufficient to disrupt latency in B lymphocytes and epithelial cells by stimulating expression of lytic cycle genes, including BRLF1. The BRLF1 product Rta functions as a 
<mark class="entity" style="background: #BF9CC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional activator
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">32</span>
</mark>
 in both B lymphocytes and epithelial cells. However, Rta has recently been reported to disrupt latency in an epithelial specific manner ( S. Zalani, E. Holley-Guthrie, and S. Kenney, Proc. Natl. Acad. Sci. USA 93:9194-9199, 1996 ) . Here we demonstrate that expression of Rta is also sufficient for disruption of latency in a permissive B-
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
. In HH514-16 cells, transfection of Rta leads to synthesis of ZEBRA, viral DNA replication, and late 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
. However, Rta by itself is less potent than ZEBRA in the ability to activate most early and late lytic cycle genes. In light of previous work implicating ZEBRA in the activation of Rta, we suggest a cooperative model for 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 entry into the lytic cycle. Expression of either BZLF1 or BRLF1 triggers expression of the other immediate-early factor, and together these activators act individually or in synergy on downstream targets to activate the viral lytic cycle. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D98438422">98438422</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Position effect of translocations involving the inactive X chromosome: physical linkage to 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    XIC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 / XIST does not lead to long-range de novo inactivation in human differentiated cells. Given the reported long-range cis-inactivating effect of the XIST gene in early embryonic development and the lack of requirement of X-chromosome-specific elements for propagating the inactive state, there exists the possibility of cis inactivation of autosomal material after de novo translocation to an inactive X chromosome ( Xi ) in differentiated cells. We have analyzed de novo radiation-induced translocations between the Xi and autosomes to study the maintenance and spreading of X-chromosome inactivation ( 
<mark class="entity" style="background: #D9CDDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X inactivation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">279</span>
</mark>
 ) in relation to the position of the 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X-inactivation center
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 ( 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    XIC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 ) /XIST in differentiated cells. Autosome / Xi translocations were detected by fluorescence in situ hybridization ( FISH ) . The activation status of the chromosomes involved in the translocation was determined by simultaneous immunocytogenetic studies using antibodies against either BrdU incorporated at late S phase or acetylated histone H4. The position of 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    XIC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 / XIST in the reciprocal products of the translocation was determined by XIST-specific FISH and computer enhancement. In other experiments, the Xq13 region carrying 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    XIC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 / XIST was localized by computer enhancement of the DAPI banding pattern. Our study in differentiated cells provides a visual demonstration that physical separation from 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    XIC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 / XIST does not result in reactivation of inactive X-chromosome material and that 
<mark class="entity" style="background: #D9CDDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X inactivation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">279</span>
</mark>
 is not spread to the translocated autosomes irrespective of the position of 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    XIC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 / XIST. This observation suggests that physical linkage to 
<mark class="entity" style="background: #EF9BBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    XIC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">153</span>
</mark>
 / XIST does not lead to de novo inactivation of autosomal material. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99005376">99005376</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Differential regulation of coproporphyrinogen oxidase gene between erythroid and 
<mark class="entity" style="background: #99FFEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonerythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">137</span>
</mark>
. Coproporphyrinogen oxidase ( CPO ) catalyzes the sixth step of the heme biosynthetic pathway. To assess the tissue-specific regulation of the CPO gene promoter, mouse genomic DNA clones for CPO were isolated. Structural analysis demonstrated that the mouse CPO gene spans approximately 11 kb and consists of seven exons, just like its human counterpart. Functional analysis of the promoter by transient transfection assays indicated that synergistic action between an SP-1-like element at -21/-12, asite at -59/-54, and a novel 
<mark class="entity" style="background: #A9999B; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    regulatory element
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">210</span>
</mark>
, CPRE ( -- ) at -49/-41, is essential for the 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
 in murine erythroleukemia ( MEL ) cells. In nonerythroid NIH3T3 cells, however, thesite is not required. Gel mobility shift assays demonstrated that specific DNA-protein complexes can be formed with each element, and that there are cell-specific differences in factors, which bind to the SP-1-like element between MEL and NIH3T3 cells. These results provide evidence for differential regulation of the promoter function of CPO gene between erythroid and 
<mark class="entity" style="background: #99FFEE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nonerythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">137</span>
</mark>
. Copyright 1998 by The American Society of Hematology </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99007236">99007236</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Inhibition of RNA polymerase II transcription in human cells by synthetic 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 ligands [see comments] Sequence-specific 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 small molecules that can permeate human cells potentially could regulate transcription of specific genes. Multiple cellular 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 are required by 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 type 1 for RNA synthesis. Two pyrrole-imidazole polyamides were designed to bind DNA sequences immediately adjacent to binding sites for the 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 Ets-1, lymphoid-enhancer binding factor 1, and TATA-box binding protein. These synthetic ligands specifically inhibit 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA-binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 of each 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 and 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    HIV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 type 1 transcription in cell-free assays. When used in combination, the polyamides inhibit virus replication by &gt;99% in isolated human 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
, with no detectable cell toxicity. The ability of small molecules to target predetermined DNA sequences located within RNA polymerase II promoters suggests a general approach for regulation of 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
, as well as a mechanism for the inhibition of viral replication. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99081619">99081619</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Mechanism of interleukin-10 inhibition of T-helper cell activation by superantigen at the level of the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
. We have analyzed the effects of interleukin-10 ( IL-10 ) on the entry of quiescent CD4 ( + ) 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 into the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
 upon stimulation with the superantigen 
<mark class="entity" style="background: #CABEF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    staphylococcal enterotoxin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">212</span>
</mark>
 B ( SEB ) . IL-10 arrested cells at G0 / G1. IL-10 treatment prevented the downregulation of p27 ( Kip1 ) , an inhibitory protein that controls progression out of the G0 phase of the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
. IL-10 also prevented the upregulation of the G1 cyclins D2 and D3, proteins necessary for entry and progression through the G1 phase of the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
. Associated with the inhibition of the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
, IL-10 suppressed SEB induction of interleukin-2 ( IL-2 ) . Addition of exogenous IL-2 to IL-10-treated cells significantly reversed the antiproliferative effects of IL-10. Moreover, IL-10 effects on the early G1 proteins p27 ( Kip1 ) and cyclin D2 were similarly reversed by exogenous IL-2. Although this reversal by IL-2 was pronounced, it was not complete, suggesting that IL-10 may have some effects not directly related to the suppression of IL-2 production. Cell separation experiments suggest that IL-10 can effect purified CD4 ( + ) 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 directly, providing functional evidence for the presence of IL-10 receptors on CD4 ( + ) 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. IL-10 also inhibited expression of IL-2 transcriptional regulators c-fos and c-jun, which also inhibit other cell functions. Our studies show that the mechanism of IL-10 regulation of quiescent CD4 ( + ) 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 is mainly by blocking induction of IL-2 that is critical to downregulation of p27 ( Kip1 ) and upregulation of D cyclins in 
<mark class="entity" style="background: #FA9DE9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T-cell activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">18</span>
</mark>
 and entry into the 
<mark class="entity" style="background: #FBBCA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell cycle
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">110</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99083144">99083144</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Effect of environmental estrogens on IL-1beta 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
 in a macrophage 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
. Environmental estrogens or estrogen disrupters have recently received a great deal of attention because of their potential health impact on reproductive tissues. Few, if any, studies have been made on the impact of these compounds on the 
<mark class="entity" style="background: #9AF9D9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    immune system
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">277</span>
</mark>
. We sought to determine the activities of various environmental estrogens on the modulation of the interleukin-1beta ( IL-1beta ) gene in a model monocytic 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
, hER + IL-1beta-CAT+. This 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 stably transfected with the human 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    estrogen receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
, and an IL-1beta promoter construct fused to the CAT reporter gene allows us to monitor the effect of estrogenic compounds on IL-1beta 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
. 17beta-estradiol ( E2 ) markedly enhanced lipopolysaccharide - ( LPS ) induced IL-1beta promoter-driven CAT activity in a dose-
<mark class="entity" style="background: #CAE9FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent manner
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">190</span>
</mark>
. The mycotoxins alpha-zearalenol and zearalenone both exhibited full agonist activity, but at lower potencies, with EC50 values of 1.8 and 54 nM, respectively, compared with E2 at 0.5 nM. In addition, genistein was a very low-potency agonist, having an EC50 of 1.5 microM. Similar to the 
<mark class="entity" style="background: #BEBE9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    E2 response
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">206</span>
</mark>
, the slope factors for alpha-zearalenol, zearalenone, and genistein were close to 3.0, suggesting positive cooperativity in the estrogenic response. The activity of the mycotoxins appeared to be mediated through the 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    estrogen receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
, since both the antiestrogens H1285 and ICI 182,780 effectively inhibited their agonist activity in a dose-
<mark class="entity" style="background: #CAE9FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent manner
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">190</span>
</mark>
. Representative environmental estrogenic compounds both from plant and industrial sources were also tested. Unlike the mycoestrogens, none of the compounds, with the exception of genistein, synergized with LPS to enhance IL-1beta 
<mark class="entity" style="background: #9BFCCD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    promoter activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">29</span>
</mark>
. When tested for antiestrogenic activity, the industrial compound 4-octylphenol was able to antagonize the 
<mark class="entity" style="background: #BEBE9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    response to E2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">206</span>
</mark>
; however, the response was three orders of magnitude less potent than H 1285. Naringenin, a plant flavonoid, showed little or no ability to antagonize the 
<mark class="entity" style="background: #BEBE9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    response to E2
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">206</span>
</mark>
. Overall, the results show that some environmental estrogens that display agonist activity in reproductive tissue also have an effect on IL-1 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in hemopoietic-derived tissue. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99091536">99091536</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Functional testosterone receptors in plasma membranes of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 are considered to be unresponsive to testosterone due to the absence of 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    androgen receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 ( 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 ) . Here, we demonstrate the testosterone responsiveness of murine splenic 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 in vitro as well as the presence of unconventional cell surface receptors for testosterone and classical intracellular 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
. Binding sites for testosterone on the surface of both CD4 ( + ) and CD8 ( + ) subsets of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 are directly revealed with the impeded ligand testosterone-BSA-FITC by confocal laser scanning microscopy ( CLSM ) and flow cytometry, respectively. Binding of the plasma membrane impermeable testosterone-BSA conjugate induces a rapid rise ( &lt;5 s ) in [Ca2+]i of Fura-2-loaded 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. This rise reflects influx of extracellular Ca2+ through non-voltage-gated and Ni2+-blockable Ca2+ channels of the plasma membrane. The testosterone-BSA-induced Ca2+ import is not affected by cyproterone, a blocker of the 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
. In addition, 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 are not detectable on the surface of intact 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 when using anti-
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 antibodies directed against the amino and carboxy terminus of the 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
, although 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 contain 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
, as revealed by reverse transcription-polymerase chain reactions and Western blotting. 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 can be visualized with the anti-
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 antibodies in the cytoplasm of permeabilized 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 by using CLSM, though 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 are not detectable in cytosol fractions when using the charcoal binding assay with 3H-R1881 as ligand. Cytoplasmic 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 do not translocate to the nucleus of 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 in the presence of testosterone, in contrast to cytoplasmic 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 in human cancer LNCaP cells. These findings suggest that the classical 
<mark class="entity" style="background: #CDC9ED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    AR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">60</span>
</mark>
 present in splenic 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 are not active in the genomic pathway. By contrast, the cell surface receptors for testosterone are in a functionally active state, enabling 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 a nongenomic response to testosterone. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99102590">99102590</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Accessing 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epstein-Barr virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
-specific T-cell memory with peptide-loaded 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dendritic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
. The conventional means of studying 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Epstein-Barr virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 ( 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 ) -induced 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cytotoxic T-lymphocyte
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 ( 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 ) memory, by in vitro stimulation with the latently infected autologous lymphoblastoid 
<mark class="entity" style="background: #BBCCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    cell line
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">130</span>
</mark>
 ( LCL ) , has important limitations. First, it gives no information on memory to lytic cycle antigens; second, it preferentially amplifies the dominant components of latent antigen-specific memory at the expense of key subdominant reactivities. Here we describe an alternative approach, based on in vitro stimulation with epitope peptide-loaded 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dendritic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 ( 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DCs
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 ) , which allows one to probe the 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 repertoire for any individual reactivity of choice; this method proved significantly more efficient than stimulation with peptide alone. Using this approach we first show that reactivities to the immunodominant and subdominant lytic cycle epitopes identified by 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 during primary 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
 infection are regularly detectable in the 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 memory of virus carriers; this implies that in such carriers chronic virus replication remains under direct T-cell control. We further show that subdominant latent cycle reactivities to epitopes in the latent membrane protein LMP2, though rarely undetectable in LCL-stimulated populations, can be reactivated by 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 stimulation and selectively expanded as polyclonal 
<mark class="entity" style="background: #9F9FDF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    CTL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">186</span>
</mark>
 lines; the adoptive transfer of such preparations may be of value in targeting certain 
<mark class="entity" style="background: #F9FC9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EBV
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">85</span>
</mark>
-positive malignancies. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99118181">99118181</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Inhibition of 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 in vitro and in vivo: role of 26S proteasome. It is becoming increasingly apparent that 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 plays a critical role in regulating the 
<mark class="entity" style="background: #FEFFFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inflammatory response
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">282</span>
</mark>
. Data obtained from studies in our laboratories demonstrate that the proteasome plays an important role in the inflammatory cascade by regulating the 
<mark class="entity" style="background: #BADD9A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of NF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">28</span>
</mark>
-kappa B. Indeed, the availability of selective and orally active proteasome inhibitors should prove useful in delineating the roles of the proteasome and 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 in other pathophysiological conditions such as cancer and heart disease. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99146379">99146379</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #9AB9AE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RFLAT-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">20</span>
</mark>
: a new zinc finger 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 that activates RANTES 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. RANTES ( Regulated upon Activation, Normal T cell Expressed and Secreted ) is a chemoattractant cytokine ( chemokine ) important in the generation of inflammatory infiltrate and 
<mark class="entity" style="background: #EDACAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human immunodeficiency virus
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">266</span>
</mark>
 entry into immune cells. RANTES is expressed late ( 3-5 days ) after activation in 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. Using expression cloning, we identified the first &quot;late&quot; 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocyte
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 associated 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 and named it &quot;
<mark class="entity" style="background: #9AB9AE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RANTES Factor of Late Activated T Lymphocytes-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">20</span>
</mark>
&quot; ( 
<mark class="entity" style="background: #9AB9AE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RFLAT-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">20</span>
</mark>
 ) . 
<mark class="entity" style="background: #9AB9AE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RFLAT-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">20</span>
</mark>
 is a novel, phosphorylated, zinc finger 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 that is expressed in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 3 days after activation, coincident with RANTES expression. While 
<mark class="entity" style="background: #9DCCAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Rel proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">309</span>
</mark>
 play the dominant role in RANTES 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 in fibroblasts, 
<mark class="entity" style="background: #9AB9AE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    RFLAT-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">20</span>
</mark>
 is a strong transactivator for RANTES in 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99155344">99155344</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Clonality of isolated eosinophils in the hypereosinophilic syndrome. The 
<mark class="entity" style="background: #DFE9BE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    idiopathic hypereosinophilic syndrome
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">272</span>
</mark>
 ( 
<mark class="entity" style="background: #DFE9BE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IHES
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">272</span>
</mark>
 ) is a rare disorder characterized by unexplained, persistent eosinophilia associated with multiple organ dysfunction due to eosinophilic tissue infiltration. In the absence of karyotypic abnormalities, there is no specific test to detect clonal eosinophilia in 
<mark class="entity" style="background: #DFE9BE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IHES
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">272</span>
</mark>
. Analysis of X-chromosome inactivation patterns can be used to determine whether proliferative disorders are clonal in origin. Methylation of HpaII and Hha I sites near the polymorphic trinucleotide repeat of the human androgen receptor gene ( HUMARA ) has been shown to correlate with 
<mark class="entity" style="background: #D9CDDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X-inactivation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">279</span>
</mark>
. In this study, we have used the 
<mark class="entity" style="background: #BFCBCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    polymerase chain reaction
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">156</span>
</mark>
 ( 
<mark class="entity" style="background: #BFCBCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">156</span>
</mark>
 ) with nested primers to analyze 
<mark class="entity" style="background: #D9CDDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X-inactivation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">279</span>
</mark>
 patterns of the HUMARA loci in purified eosinophils from female patients with eosinophilia. 
<mark class="entity" style="background: #BBEFAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Peripheral blood
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">97</span>
</mark>
 eosinophils were isolated by their autofluoresence using flow cytometric sorting. Eosinophils purified from a female patient presenting with 
<mark class="entity" style="background: #DFE9BE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IHES
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">272</span>
</mark>
 were found to show a clonal pattern of 
<mark class="entity" style="background: #D9CDDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X-inactivation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">279</span>
</mark>
. Eosinophil-depleted leukocytes from this patient were polyclonal by HUMARA analysis, thus excluding skewedness of random 
<mark class="entity" style="background: #D9CDDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X-inactivation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">279</span>
</mark>
. After corticosteroid suppression of her blood eosinophilia, a clonal population of eosinophils could no longer be detected in purified eosinophils. In contrast, eosinophils purified from a patient with Churg-Strauss syndrome and from six patients with reactive eosinophilias attributed to allergy, parasitic infection, or drug reaction showed a polyclonal pattern of 
<mark class="entity" style="background: #D9CDDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    X-inactivation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">279</span>
</mark>
 by HUMARA analysis. The finding of clonal eosinophilia in a patient presenting with 
<mark class="entity" style="background: #DFE9BE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IHES
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">272</span>
</mark>
 indicates that such patients may have, in reality, a low-grade clonal disorder that can be distinguished from reactive eosinophilias by HUMARA analysis. Further, the method described can be used to monitor disease progression. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99168986">99168986</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Interferon-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 activates multiple 
<mark class="entity" style="background: #BC99FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    STAT proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">310</span>
</mark>
 and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Interferon-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 ( 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 ) is a pleiotropic cytokine that has antiviral, antiproliferative, and immunoregulatory functions. There is increasing evidence that 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 has an important role in T-cell biology. We have analyzed the expression of IL-2Ralpha, c-myc, and pim-1 genes in anti-CD3-activated human 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
. The induction of these genes is associated with interleukin-2 ( IL-2 ) -induced T-cell proliferation. Treatment of 
<mark class="entity" style="background: #AF9EF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">299</span>
</mark>
 with 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
, IL-2, IL-12, and IL-15 upregulated IL-2Ralpha, c-myc, and pim-1 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
. 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 also sensitized 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 to IL-2-induced proliferation, further suggesting that 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 may be involved in the regulation of T-cell mitogenesis. When we analyzed the nature of 
<mark class="entity" style="background: #BC99FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    STAT proteins
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">310</span>
</mark>
 capable of binding to IL-2Ralpha, pim-1, and IRF-1 GAS elements after cytokine stimulation, we observed 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
-induced binding of STAT1, STAT3, and STAT4, but not STAT5 to all of these elements. Yet, 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 was able to activate binding of STAT5 to the high-affinity IFP53 GAS site. 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 enhanced 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of STAT1, STAT3, STAT4, STAT5a, and STAT5b. IL-12 induced STAT4 and IL-2 and IL-15 induced STAT5 binding to the GAS elements. Taken together, our results suggest that 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
, IL-2, IL-12, and IL-15 have overlapping activities on human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. These findings thus emphasize the importance of 
<mark class="entity" style="background: #BFEAC9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IFN-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">54</span>
</mark>
 as a T-cell regulatory cytokine. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99172186">99172186</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">N-acetyl-L-cysteine inhibits primary human T cell responses at the 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dendritic cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 level: association with 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 inhibition. N-acetyl-L-cysteine ( NAC ) is an antioxidant molecule endowed with immunomodulatory properties. To investigate the effect of NAC on the induction phase of T cell responses, we analyzed its action on human 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dendritic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 ( 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 ) derived from adherent PBMC cultured with IL-4 and granulocyte-macrophage CSF. We first found that NAC inhibited the constitutive as well as the LPS-induced activity of the 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 NF-kappa B. In parallel, NAC was shown to down-regulate the 
<mark class="entity" style="background: #ECEAED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    production of cytokines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">183</span>
</mark>
 by 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 as well as their surface expression of HLA-DR, CD86 ( B7-2 ) , and CD40 molecules both at the basal state and upon LPS activation. NAC also inhibited 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 responses induced by CD40 engagement. The inhibitory effects of NAC were not due to nonspecific toxicity as neither the viability of 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 nor their mannose receptor-mediated endocytosis were modified by NAC. Finally, we found that the addition of NAC to MLR between naive 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
 and allogeneic 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 resulted in a profound inhibition of alloreactive responses, which could be attributed to a defect of 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
 as APC-independent T cell responses were not inhibited by NAC. Altogether, our results suggest that NAC might impair the generation of primary immune responses in humans through its inhibitory action on 
<mark class="entity" style="background: #ADBBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">111</span>
</mark>
. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99201482">99201482</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Inhibition of cyclooxygenase-2 expression by 4-trifluoromethyl derivatives of salicylate, triflusal, and its deacetylated metabolite, 2-hydroxy-4-
<mark class="entity" style="background: #CDEDA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trifluoromethylbenzoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">9</span>
</mark>
. The therapeutic potential of drugs that block the induction of cyclooxygenase-2 has been emphasized. When two 4-trifluoromethyl salicylate derivatives [2-acetoxy-4-
<mark class="entity" style="background: #CDEDA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trifluoromethyl-benzoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">9</span>
</mark>
 ( triflusal ) and its deacetylated metabolite 2-hydroxy-4-
<mark class="entity" style="background: #CDEDA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    trifluoromethylbenzoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">9</span>
</mark>
 ( HTB ) ] were compared with aspirin and sodium salicylate as cyclooxygenase-2 ( COX-2 ) inhibitors, we observed that in bacterial lipopolysaccharide-activated human blood, triflusal, aspirin, and HTB, but not sodium salicylate, inhibited COX-2-mediated prostaglandin E2 ( PGE2 ) production ( IC50 = 0.16, 0.18, 0.39, and &gt;10 mM, respectively ) . However, only triflusal and aspirin inhibited purified COX-2 enzyme. To test this apparent discrepancy, we realized that HTB and triflusal ( but neither aspirin nor salicylate ) produced a concentration-dependent inhibition of COX-2 protein expression in peripheral human mononuclear cells. This observation was further confirmed in a rat air pouch model in vivo, in which both aspirin and triflusal inhibited PGE2 production ( ID50 = 18.9 and 11.4 mg / kg p.o., respectively ) but only triflusal-treated animals showed a decrease in COX-2 expression. This different behavior may be, at least in part, due to the ability of HTB and triflusal to block the activation of the 
<mark class="entity" style="background: #AEBAAA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">77</span>
</mark>
 to a higher extent than aspirin and sodium salicylate. Thus, in addition to inhibiting the COX-2 activity at therapeutic concentrations, triflusal is able to block through its metabolite HTB the expression of new enzyme, and hence the resumption of PGE2 synthesis. Triflusal and HTB may exert beneficial effects in processes in which de novo COX-2 expression is involved and, in a broader sense, in pathological situations in which genes under 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 control are up-regulated. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99207658">99207658</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">[Corticoids and allergy] Inflammation is constantly observed in allergic reactions. Corticosteroids are most effective in preventing the late phase of allergic reaction. The action of glucocorticosteroids is mediated through 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 present in the cellular cytoplasm. When activated, 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 form a dimer and 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bind to DNA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 after migration into the nucleus. Interaction to DNA induces changes in the transcription rate, leading to either gene induction or gene repression. 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Glucocorticoid receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 are also able to interact with 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcriptional factors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 such as AP-1 ( activator protein-1 ) of 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) . Through these actions glucocorticosteroids are susceptible to modify functions of cells involved in the allergic 
<mark class="entity" style="background: #FEFFFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    inflammatory response
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">282</span>
</mark>
. They are in particular able to inhibit most of the pro-inflammatory functions of the eosinophils. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99228708">99228708</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">LPS-Induced 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and 
<mark class="entity" style="background: #FBDFAE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release in human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">48</span>
</mark>
 are 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 dependent and 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein kinase C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 independent. BACKGROUND: 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Tumor necrosis factor alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ( 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ) is an important mediator of septic shock. Endotoxin ( LPS ) signal transduction in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 leads to 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of nuclear factor-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 ) and 
<mark class="entity" style="background: #FFABBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">50</span>
</mark>
. Previous studies have implicated activation of both 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein kinase C
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 ( 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 ) and 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinases
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 ( 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 ) in LPS-induced 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 production. We hypothesized that inhibition of either 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 or 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 would decrease LPS-induced 
<mark class="entity" style="background: #ACF9FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">69</span>
</mark>
 and 
<mark class="entity" style="background: #FBDFAE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release in human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">48</span>
</mark>
. MATERIALS AND METHODS: 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 were stimulated with PMA ( 50 ng / ml ) alone or LPS ( 100 ng / ml ) with and without a nonspecific serine / threonine protein kinase inhibitor staurosporine ( Stauro ) , a specific pan-
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 inhibitor bisindolylmaleimide ( Bis ) , or an inhibitor of 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 genistein ( Gen ) . 
<mark class="entity" style="background: #FFABBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">50</span>
</mark>
 in culture supernatants was measured by an ELISA. 
<mark class="entity" style="background: #ACF9FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">69</span>
</mark>
 was evaluated by 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    electrophoretic mobility shift assay
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
. RESULTS: LPS increased 
<mark class="entity" style="background: #ACF9FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">69</span>
</mark>
 and 
<mark class="entity" style="background: #FBDFAE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release in human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">48</span>
</mark>
. Nonspecific protein kinase inhibition inhibited 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and 
<mark class="entity" style="background: #FFABBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">50</span>
</mark>
, while specific 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 inhibition with Bis had no effect on LPS-induced 
<mark class="entity" style="background: #ACF9FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">69</span>
</mark>
 or 
<mark class="entity" style="background: #FFABBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">50</span>
</mark>
. 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 inhibition with Gen attenuated both LPS-induced 
<mark class="entity" style="background: #ACF9FD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">69</span>
</mark>
 and 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 production in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. Direct activation of 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 with PMA induced both 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 production by 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. CONCLUSIONS: These results suggest that LPS-induced 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and 
<mark class="entity" style="background: #FBDFAE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release in human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">48</span>
</mark>
 are independent of 
<mark class="entity" style="background: #DE9A9C; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PKC
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">100</span>
</mark>
 activity. Furthermore, our results provide evidence that 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PTK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 plays a role in LPS-induced 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and 
<mark class="entity" style="background: #FBDFAE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha release in human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">48</span>
</mark>
 and thus could be a potential therapeutic target in inflammatory states.</div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99294118">99294118</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Binding characteristics of the 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
 in multiple sclerosis. Although the exact etiology of multiple sclerosis ( MS ) remains unresolved, immune reactions are believed to be the central pathogenic mechanisms. Endogenous and therapeutic steroid hormones affect the 
<mark class="entity" style="background: #9AF9D9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    immune system
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">277</span>
</mark>
, and inflammatory diseases are associated with activation of the hypothalamic-pituitary-adrenal axis, providing evidence of an immune-endocrine interplay. Function tests in MS have revealed dysregulation of the hypothalamic-pituitary-adrenal system in a substantial proportion of patients. We characterized 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ( 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 ) binding in 
<mark class="entity" style="background: #FEEBBF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    peripheral blood lymphocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">95</span>
</mark>
 from 39 MS patients and 14 age- and sex-matched controls with respect to dissociation constant and binding capacity, using a whole-cell binding assay with [3H]dexamethasone as the ligand. 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 binding parameters did not differ significantly between patients ( Kd 8.98 +/- 1.07 nM, Bmax 183 +/- 29.8 fmol / mg ) and controls ( Kd 9.36 +/- 1.17 nM, Bmax 158 +/- 16 fmol / mg ) . No effect of age, sex, course, duration or severity of disease, or prior steroid treatments was detected. 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 binding parameters were analyzed in relation to the results of the combined dexamethasone-CRH test, which reflects corticosteroid receptor function at the hypothalamus, in 30 patients and 9 controls. While controls showed a moderate correlation between binding affinity of the 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 in lymphocytes and regulatory function at the hypothalamic level, the patients did not. These data suggest that the physiological relationship between binding and function of the 
<mark class="entity" style="background: #DABBCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    glucocorticoid receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">254</span>
</mark>
 is disturbed in MS. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99305241">99305241</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Signal transduction pathways in normal 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 stimulated by cytokines and mediators: comparative study with normal human neutrophils or transformed cells and the putative roles in functionality and cell biology. 
<mark class="entity" style="background: #9CFEBD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Granulocyte-macrophage colony
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">161</span>
</mark>
-stimulating factor ( 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 ) and interleukin ( IL ) -3 induced 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of 92-kDa protein in normal 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. We identified this 92-kDa protein as STAT5, but not as STATs1, 3, and 6 nor c-fes and vav protooncogene products, and demonstrated its translocation to the nucleus, enhancement of specific 
<mark class="entity" style="background: #9FEEED; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    DNA binding
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">91</span>
</mark>
 capacity, and potentiation of trancriptional activity by 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
. N-
<mark class="entity" style="background: #AAFDCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    formyl-methionyl-leucyl-phenylalanine
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">243</span>
</mark>
 ( 
<mark class="entity" style="background: #AAFDCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FMLP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">243</span>
</mark>
 ) and 
<mark class="entity" style="background: #EF9DBE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    phorbol myristate acetate
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">4</span>
</mark>
 ( PMA ) induced 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 of 42- and 44-kDa proteins, which were identified as extracellular signal-regulated kinase ( ERK ) , in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. In marked contrast to neutrophils and MO7e cells, 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 did not induce 
<mark class="entity" style="background: #FDEDCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tyrosine phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">308</span>
</mark>
 and activation of ERK in monocytes. Among upstream signaling molecules of ERK, Shc was constitutively associated with Grb2 and was not tyrosine-phosphorylated by 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 and 
<mark class="entity" style="background: #AAFDCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FMLP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">243</span>
</mark>
, and Sos1 and c-Raf-1 were not phosphorylated by 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
, IL-3, 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
, and 
<mark class="entity" style="background: #AAFDCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FMLP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">243</span>
</mark>
 in monocytes, whereas all these signaling molecules were affected and / or utilized by 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 in MO7e cells. In contrast to neutrophils, p38 was constitutively phosphorylated and agonist-
<mark class="entity" style="background: #FA9BBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent phosphorylation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">191</span>
</mark>
 and activation was not detected in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. Superoxide release stimulated by 
<mark class="entity" style="background: #AAFDCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FMLP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">243</span>
</mark>
 was inhibited partially by PD98059 or SB203580, a specific inhibitor of ERK or p38 pathway, and was almost completely inhibited by the combination of both inhibitors, whereas PMA-induced superoxide release was resistant to these two inhibitors in monocytes. PD98059 inhibited 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
-dependent proliferation of MO7e cells. Present results indicate trancriptional roles of STAT5 and functional roles of ERK and / or p38 in normal 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
 stimulated by physiological receptor-mediated agonists 
<mark class="entity" style="background: #B9DBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    GM-CSF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">177</span>
</mark>
 and 
<mark class="entity" style="background: #AAFDCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    FMLP
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">243</span>
</mark>
. Possible roles of ERK in proliferation of transformed cells were also suggested. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99310627">99310627</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">GATA-1 and erythropoietin cooperate to promote 
<mark class="entity" style="background: #A9CFCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell survival
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">120</span>
</mark>
 by regulating 
<mark class="entity" style="background: #BBB9B9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bcl-xL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">86</span>
</mark>
 expression. The 
<mark class="entity" style="background: #C9EFBC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    transcription factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">237</span>
</mark>
 GATA-1 is essential for normal erythropoiesis. By examining in vitro-differentiated embryonic stem cells, we showed previously that in the absence of GATA-1, committed erythroid precursors fail to complete maturation and instead undergo apoptosis. The mechanisms by which GATA-1 controls cell survival are unknown. Here we report that in 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
, GATA-1 strongly induces the expression of the anti-apoptotic protein 
<mark class="entity" style="background: #BBB9B9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bcl-xL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">86</span>
</mark>
, but not the related proteins bcl-2 and mcl-1. Consistent with a role for 
<mark class="entity" style="background: #BBB9B9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bcl-xL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">86</span>
</mark>
 in mediating GATA-1-induced 
<mark class="entity" style="background: #A9CFCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell survival
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">120</span>
</mark>
, in vitro-differentiated bcl-xL-/- embryonic stem cells fail to generate viable mature definitive 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
, a phenotype resembling that of GATA-1 gene disruption. In addition, we show that erythropoietin, which is also required for 
<mark class="entity" style="background: #A9CFCE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell survival
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">120</span>
</mark>
, cooperates with GATA-1 to stimulate 
<mark class="entity" style="background: #BBB9B9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bcl-xL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">86</span>
</mark>
 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 and to maintain 
<mark class="entity" style="background: #FAADBB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    erythroid cell
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">118</span>
</mark>
 viability during terminal maturation. Together, our data show that 
<mark class="entity" style="background: #BBB9B9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bcl-xL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">86</span>
</mark>
 is essential for normal erythroid development and suggest a regulatory hierarchy in which 
<mark class="entity" style="background: #BBB9B9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    bcl-xL
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">86</span>
</mark>
 is a critical downstream effector of GATA-1 and erythropoietin-mediated signals. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99356019">99356019</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Reactive oxygen intermediate-release of fibre-exposed monocytes increases inflammatory cytokine-mRNA level, 
<mark class="entity" style="background: #ECF9CE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">288</span>
</mark>
 and 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 in co-cultured bronchial epithelial cells ( BEAS-2B ) . Some pulmonary diseases like bronchitis or asthma bronchiale are mediated by inflammatory mechanisms in bronchial epithelial cells. Alveolar macrophages are located directly in the surrounding of these cells, so that we suppose an interaction between epithelial cells and macrophages regarding to the release of inflammatory mediators. For measuring the contribution of macrophages to the release of inflammatory mediators by bronchial epithelial cells, we established an in vitro model of co-cultured blood monocytes ( BM ) and BEAS-2B cells in a transwell system ( Costar ) . BM were exposed to Chrysotile B and soot particle FR 101 in a concentration of 100 microg / 10 ( 6 ) cells. After up to 90 min exposure time ELISA, 
<mark class="entity" style="background: #DCFA99; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    EMSA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">65</span>
</mark>
 ( electromobility shift assay ) and RT-
<mark class="entity" style="background: #BFCBCA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    PCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">156</span>
</mark>
 were used to measure 
<mark class="entity" style="background: #CDADB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinase activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">25</span>
</mark>
, protein 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activity of NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
 and cytokine ( IL-1beta, IL-6, 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 ) specific mRNA levels in BEAS-2B cells. We observed an increase in 
<mark class="entity" style="background: #CDADB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    protein tyrosine kinase activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">25</span>
</mark>
 ( up to 1.8 +/- 0.5-fold ) and 
<mark class="entity" style="background: #BCFEDA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B protein
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">76</span>
</mark>
 activity in BEAS-2B cells after particle or fibre exposure of co-cultured BM. Consecutive IL-1beta-, IL-6- and 
<mark class="entity" style="background: #EEEDD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha-mRNA
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">49</span>
</mark>
 were elevated ( up to 1.9 +/- 0.58-fold ) . 
<mark class="entity" style="background: #CDADB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Protein tyrosine kinase activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">25</span>
</mark>
, 
<mark class="entity" style="background: #ACCBD9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B activity
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">15</span>
</mark>
, and the synthesis of cytokine-specific mRNA were inhibited by antioxidants. These data suggest a ROI-dependent 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 mediated transcription of inflammatory cytokines in bronchial epithelial cells. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99357866">99357866</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. The generation of cell-mediated immunity against many infectious pathogens involves the production of interleukin-12 ( IL-12 ) , a key signal of the innate 
<mark class="entity" style="background: #9AF9D9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    immune system
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">277</span>
</mark>
. Yet, for many pathogens, the molecules that induce IL-12 production by macrophages and the mechanisms by which they do so remain undefined. Here it is shown that microbial lipoproteins are potent stimulators of IL-12 production by human macrophages, and that induction is mediated by Toll-like receptors ( TLRs ) . Several lipoproteins stimulated TLR-dependent transcription of inducible nitric oxide synthase and the production of nitric oxide, a powerful microbicidal pathway. Activation of TLRs by microbial lipoproteins may initiate innate defense mechanisms against infectious pathogens. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99369970">99369970</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Cutting edge: 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 stimulation by antibody and bacterial superantigen induces 
<mark class="entity" style="background: #DEFD9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Stat3 activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">31</span>
</mark>
 in human 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Recent data show that 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 / CD3 stimulation induces activation of Stat5 in murine 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Here, we show that CD3 ligation by mAb and 
<mark class="entity" style="background: #CABEF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Staphylococcal enterotoxin
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">212</span>
</mark>
 ( 
<mark class="entity" style="background: #CABEF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">212</span>
</mark>
 ) induce a rapid, gradually accumulating, long-lasting tyrosine, and 
<mark class="entity" style="background: #FEF9AD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    serine phosphorylation of Stat3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">307</span>
</mark>
 ( but not Stat5 ) in allogen-specific human CD4+ 
<mark class="entity" style="background: #DEC9DE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cell lines
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">133</span>
</mark>
. In contrast, IL-2 induces a rapid and transient tyrosine and 
<mark class="entity" style="background: #FEF9AD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    serine phosphorylation of Stat3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">307</span>
</mark>
. Compared with IL-2, CD3 ligation induces a delayed Stat3 binding to oligonucleotide probes from the 
<mark class="entity" style="background: #EFDEA9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    ICAM-1
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">38</span>
</mark>
 and IL-2R alpha promoter. CD3-mediated 
<mark class="entity" style="background: #DEFD9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    activation of Stat3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">31</span>
</mark>
 is almost completely inhibited by a Src kinase inhibitor ( PP1 ) , whereas IL-2-induced 
<mark class="entity" style="background: #DEFD9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Stat3 activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">31</span>
</mark>
 is unaffected. In conclusion, we show that CD3 ligation by mAb and 
<mark class="entity" style="background: #CABEF9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    SE
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">212</span>
</mark>
 triggers a rapid, PP1-sensitive tyrosine and 
<mark class="entity" style="background: #FEF9AD; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    serine phosphorylation of Stat3
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">307</span>
</mark>
 in human CD4+ 
<mark class="entity" style="background: #DAEFEB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    T cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">144</span>
</mark>
. Moreover, we provide evidence that 
<mark class="entity" style="background: #BCCE9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TCR
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">142</span>
</mark>
 / CD3 and IL-2 induce 
<mark class="entity" style="background: #DEFD9E; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Stat3 activation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">31</span>
</mark>
 via distinct signaling pathways. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99386936">99386936</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Differential effects of lipopolysaccharide and 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 on monocytic Ikappa B kinase signalsome activation and Ikappa B proteolysis. The inflammatory mediators lipopolysaccharide ( LPS ) and 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    tumor necrosis factor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ( 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 ) are potent activators of NF-kappa B. This study compared the effect of these stimuli on endogenous Ikappa B kinase ( IKK ) signalsome activation and Ikappa B phosphorylation / proteolysis in human 
<mark class="entity" style="background: #DBEFB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocytic cells
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">135</span>
</mark>
 and investigated the role of the signalsome proteins 
<mark class="entity" style="background: #9FBB9D; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">53</span>
</mark>
, 
<mark class="entity" style="background: #9FBDDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-beta
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">89</span>
</mark>
, 
<mark class="entity" style="background: #C999FB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B-inducing kinase
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">73</span>
</mark>
 ( 
<mark class="entity" style="background: #C999FB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NIK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">73</span>
</mark>
 ) , IKK-gamma ( 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 essential modulator ) , and IKK complex-associated protein. Kinase assays showed that 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 elicited a rapid but short-lived induction of IKK activity with a 3-fold greater effect on 
<mark class="entity" style="background: #9FBB9D; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">53</span>
</mark>
 than on 
<mark class="entity" style="background: #9FBDDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-beta
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">89</span>
</mark>
, peaking at 5 min. In contrast, LPS predominantly stimulated 
<mark class="entity" style="background: #9FBDDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-beta
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">89</span>
</mark>
 activity, which slowly increased, peaking at 30 min. A second peak was observed at a later time point following 
<mark class="entity" style="background: #AAFAAB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    LPS stimulation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">295</span>
</mark>
, which consisted of both 
<mark class="entity" style="background: #9FBB9D; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">53</span>
</mark>
 and -beta activity. The endogenous levels of the signalsome components were unaffected by stimulation. Furthermore, our studies showed association of the 
<mark class="entity" style="background: #9FBB9D; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">53</span>
</mark>
 / beta heterodimer with 
<mark class="entity" style="background: #C999FB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NIK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">73</span>
</mark>
, Ikappa B-alpha and -epsilon in unstimulated cells. Exposure to LPS or 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
 led to differential patterns of Ikappa B-alpha and Ikappa B-epsilon disappearance from and reassembly with the signalsome, whereas 
<mark class="entity" style="background: #9FBB9D; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">53</span>
</mark>
, 
<mark class="entity" style="background: #9FBDDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-beta
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">89</span>
</mark>
, and 
<mark class="entity" style="background: #C999FB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NIK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">73</span>
</mark>
 remained complex-associated. 
<mark class="entity" style="background: #C999FB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NIK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">73</span>
</mark>
 cannot phosphorylate Ikappa B-alpha directly, but it appears to be a functionally important subunit, because mutated 
<mark class="entity" style="background: #C999FB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NIK
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">73</span>
</mark>
 inhibited stimulus-induced kappa B-dependent transcription more effectively than mutated 
<mark class="entity" style="background: #9FBB9D; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    IKK-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">53</span>
</mark>
 or -beta. Overexpression of IKK complex-associated protein inhibited stimulus-mediated transcription, whereas 
<mark class="entity" style="background: #EA9EFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    NF-kappa B
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">75</span>
</mark>
 essential modulator enhanced it. The understanding of LPS- and 
<mark class="entity" style="background: #EAD9EE; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">231</span>
</mark>
-induced signaling may allow the development of specific strategies to treat sepsis-associated disease. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99394774">99394774</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Gender and vascular reactivity. 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Estrogen receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 are found on vascular endothelial and smooth muscle cells; their expression is influenced by exposure to the hormone. 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Estrogen receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 influence non-genomic events, which are rapid in onset and genomic events, which are longer acting responses. Estrogens affect vascular tone indirectly by modulating release of endothelium-derived vasoactive factors and directly by modulating intracellular calcium in vascular smooth muscle cells. Estrogens indirectly affect thrombotic events and inflammation by altering platelet aggregation and leukocyte adherence and migration, respectively. Estrogens also influence production of mitogens which, when released at sites of vascular injury, affect vascular remodeling. Although estrogens initiate vascular responses, genomic sex may influence and / or limit expression of 
<mark class="entity" style="background: #CAE99A; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    estrogen receptors
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">217</span>
</mark>
 and therefore actions of sex steroid hormones throughout the vasculature. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99406845">99406845</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">Glucocorticoids induce apoptosis in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
: potential role of IL-1 beta. Glucocorticoids ( GC ) are potent anti-inflammatory and immunosuppressive agents that act on a variety of immune cells, including monocytes and macrophages. However, the exact cellular mechanisms underlying this anti-inflammatory capacity are still unknown. In our study, we determined the 
<mark class="entity" style="background: #9FAEBA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    induction of apoptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">63</span>
</mark>
 by GC in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. 
<mark class="entity" style="background: #AEBDFF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Peripheral blood monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">96</span>
</mark>
 were isolated by density centrifugation methods with a purity of &gt;90% and were cultured in RPMI 1640 medium. 
<mark class="entity" style="background: #FACEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Monocyte apoptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">64</span>
</mark>
 was determined by four independent methods, including annexin-V staining, TUNEL, DNA-laddering, and typical morphology by means of transmission electron microscopy. 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 and IL-1beta were measured by ELISA. GC receptor was blocked with mifepristone. Caspase 3 was inhibited with caspase-3 inhibitor ( DEVD-CHO ) . Stimulation with different GC at therapeutic concentrations resulted in 
<mark class="entity" style="background: #FACEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocyte apoptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">64</span>
</mark>
 in a time- and dose-
<mark class="entity" style="background: #CAE9FA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    dependent manner
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">190</span>
</mark>
. Necrosis was excluded by propidium iodide staining. Proinflammatory cytokines such as IL-1beta and 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
 were down-regulated by GC treatment. Continuous treatment of monocytes with IL-1beta, but not with 
<mark class="entity" style="background: #EAF9DB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    TNF-alpha
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">52</span>
</mark>
, could almost completely prevent GC-induced cell death. The addition of mifepristone or caspase-3 inhibitor could partially abrogate GC-induced apoptosis as well as GC-induced inhibition of IL-1beta. This is the first study to demonstrate 
<mark class="entity" style="background: #9FAEBA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    induction of apoptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">63</span>
</mark>
 by GC in 
<mark class="entity" style="background: #FADBB9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    human monocytes
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">269</span>
</mark>
. GC-induced 
<mark class="entity" style="background: #FACEAF; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    monocyte apoptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">64</span>
</mark>
 may be partially mediated through effects on IL-1beta production. It is conceivable that GC exert their anti-inflammatory capacity in various diseases, at least in part, by the 
<mark class="entity" style="background: #9FAEBA; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    induction of apoptosis
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">63</span>
</mark>
 in monocytes. </div>
</figure>

<figure style="margin-bottom: 6rem">
<h2 style="margin: 0" id="D99408303">99408303</h2>

<div class="entities" style="line-height: 2.5; direction: ltr">
<mark class="entity" style="background: #99CCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neutrophil maturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">300</span>
</mark>
 and the role of 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
. 
<mark class="entity" style="background: #99CCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Neutrophil maturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">300</span>
</mark>
 occurs in well defined morphological stages that correlate with the acquisition of molecular markers associated with neutrophil function. A variety of factors are known to play a role in terminal 
<mark class="entity" style="background: #99CCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neutrophil maturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">300</span>
</mark>
, including the vitamin A derivative, 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
. 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    Retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 can directly modulate 
<mark class="entity" style="background: #CCEBDC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    gene expression
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">218</span>
</mark>
 via binding to its nuclear receptors, which can, in turn, activate transcription of target genes. A role for 
<mark class="entity" style="background: #CDB9E9; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">12</span>
</mark>
 during 
<mark class="entity" style="background: #99CCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neutrophil maturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">300</span>
</mark>
 has been suggested from a variety of sources. Here we present a review of the mechanism of 
<mark class="entity" style="background: #EACEFB; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    retinoic acid receptor
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">11</span>
</mark>
 action and the major evidence showing that normal retinoid signaling is required for 
<mark class="entity" style="background: #99CCEC; padding: 0.45em 0.6em; margin: 0 0.25em; line-height: 1; border-radius: 0.35em;">
    neutrophil maturation
    <span style="font-size: 0.8em; font-weight: bold; line-height: 1; border-radius: 0.35em; vertical-align: middle; margin-left: 0.5rem">300</span>
</mark>
. </div>
</figure>
</body>
</html>